EP1414853A2 - Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon - Google Patents
Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereonInfo
- Publication number
- EP1414853A2 EP1414853A2 EP01995938A EP01995938A EP1414853A2 EP 1414853 A2 EP1414853 A2 EP 1414853A2 EP 01995938 A EP01995938 A EP 01995938A EP 01995938 A EP01995938 A EP 01995938A EP 1414853 A2 EP1414853 A2 EP 1414853A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- expression
- protein
- genes
- gene
- angiogenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 102
- 210000000936 intestine Anatomy 0.000 title claims abstract description 39
- 244000005706 microflora Species 0.000 title claims abstract description 30
- 230000000694 effects Effects 0.000 title claims description 32
- 238000011282 treatment Methods 0.000 title claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 12
- 201000010099 disease Diseases 0.000 title description 9
- 230000002496 gastric effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 170
- 230000014509 gene expression Effects 0.000 claims abstract description 107
- 238000011161 development Methods 0.000 claims abstract description 9
- 238000011156 evaluation Methods 0.000 claims abstract description 8
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 5
- 101710190945 Angiogenin-4 Proteins 0.000 claims description 51
- 241000894006 Bacteria Species 0.000 claims description 44
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims description 38
- 230000004044 response Effects 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 27
- 235000018102 proteins Nutrition 0.000 claims description 27
- 108020002632 colipase Proteins 0.000 claims description 26
- 102000005311 colipase Human genes 0.000 claims description 25
- 230000006870 function Effects 0.000 claims description 25
- 238000004458 analytical method Methods 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 101710190946 Angiogenin-3 Proteins 0.000 claims description 20
- 108010009575 CD55 Antigens Proteins 0.000 claims description 17
- 108010072788 angiogenin Proteins 0.000 claims description 17
- 102000003792 Metallothionein Human genes 0.000 claims description 16
- 108090000157 Metallothionein Proteins 0.000 claims description 16
- 108090001060 Lipase Proteins 0.000 claims description 14
- 102100040402 Phlorizin hydrolase Human genes 0.000 claims description 14
- 230000000968 intestinal effect Effects 0.000 claims description 14
- 101100139845 Caenorhabditis elegans rac-2 gene Proteins 0.000 claims description 13
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims description 13
- 108091022862 fatty acid binding Proteins 0.000 claims description 13
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 claims description 12
- 238000002474 experimental method Methods 0.000 claims description 12
- 108010032748 Cornified Envelope Proline-Rich Proteins Proteins 0.000 claims description 11
- 102000007356 Cornified Envelope Proline-Rich Proteins Human genes 0.000 claims description 11
- 101100310678 Mus musculus Sprr2a1 gene Proteins 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 11
- 230000004060 metabolic process Effects 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 108010070675 Glutathione transferase Proteins 0.000 claims description 9
- 108010059801 Lactase-Phlorizin Hydrolase Proteins 0.000 claims description 9
- 210000000105 enteric nervous system Anatomy 0.000 claims description 9
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 8
- 102100022987 Angiogenin Human genes 0.000 claims description 8
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 claims description 8
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 claims description 8
- 101000693095 Mus musculus Angiopoietin-related protein 4 Proteins 0.000 claims description 8
- 230000008238 biochemical pathway Effects 0.000 claims description 8
- 108091004554 Copper Transport Proteins Proteins 0.000 claims description 7
- 102000037773 Copper transporters Human genes 0.000 claims description 7
- 108091006566 Copper transporters Proteins 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 claims description 7
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 7
- 230000018109 developmental process Effects 0.000 claims description 7
- 230000007358 intestinal barrier function Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 238000001784 detoxification Methods 0.000 claims description 6
- -1 endoB cyto eratin Proteins 0.000 claims description 6
- 230000004682 mucosal barrier function Effects 0.000 claims description 6
- 102000034534 Cotransporters Human genes 0.000 claims description 5
- 108020003264 Cotransporters Proteins 0.000 claims description 5
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 claims description 5
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 claims description 5
- 229930195714 L-glutamate Natural products 0.000 claims description 5
- 108010046644 Polymeric Immunoglobulin Receptors Proteins 0.000 claims description 5
- 102000001253 Protein Kinase Human genes 0.000 claims description 5
- 101100497134 Rattus norvegicus Cyp2d26 gene Proteins 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 5
- 230000004890 epithelial barrier function Effects 0.000 claims description 5
- 230000019491 signal transduction Effects 0.000 claims description 5
- 108010002084 Apoferritins Proteins 0.000 claims description 4
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 239000013043 chemical agent Substances 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 235000021062 nutrient metabolism Nutrition 0.000 claims description 4
- 235000021231 nutrient uptake Nutrition 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 claims description 3
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 3
- 108010085238 Actins Proteins 0.000 claims description 3
- 102000000546 Apoferritins Human genes 0.000 claims description 3
- 102100031621 Cysteine and glycine-rich protein 2 Human genes 0.000 claims description 3
- 101710185482 Cysteine and glycine-rich protein 2 Proteins 0.000 claims description 3
- 101710202823 Cysteine-rich protein 2 Proteins 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
- 102000004878 Gelsolin Human genes 0.000 claims description 3
- 108090001064 Gelsolin Proteins 0.000 claims description 3
- 101000932178 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 claims description 3
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 claims description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000002744 extracellular matrix Anatomy 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 238000012606 in vitro cell culture Methods 0.000 claims description 3
- 229940049920 malate Drugs 0.000 claims description 3
- 230000001785 maturational effect Effects 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000159 protein binding assay Methods 0.000 claims description 3
- 108060006633 protein kinase Proteins 0.000 claims description 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 2
- 108091006112 ATPases Proteins 0.000 claims description 2
- 101710170648 Actin, alpha cardiac muscle 1 Proteins 0.000 claims description 2
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 claims description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 2
- 102000000584 Calmodulin Human genes 0.000 claims description 2
- 108010041952 Calmodulin Proteins 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 108010022452 Collagen Type I Proteins 0.000 claims description 2
- 108090000082 Destrin Proteins 0.000 claims description 2
- 102000003668 Destrin Human genes 0.000 claims description 2
- 101100451497 Dictyostelium discoideum hspB gene Proteins 0.000 claims description 2
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 claims description 2
- 101710111663 Egl nine homolog 1 Proteins 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 108010063907 Glutathione Reductase Proteins 0.000 claims description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims description 2
- 101150022862 HSC70 gene Proteins 0.000 claims description 2
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 claims description 2
- 108010042653 IgA receptor Proteins 0.000 claims description 2
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims description 2
- 101710166699 Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims description 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims description 2
- 108020002496 Lysophospholipase Proteins 0.000 claims description 2
- 101100228910 Mus musculus Gipc2 gene Proteins 0.000 claims description 2
- 101710170720 Prolyl hydroxylase EGLN3 Proteins 0.000 claims description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 2
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 claims description 2
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 2
- 101710190759 Serum amyloid A protein Proteins 0.000 claims description 2
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 claims description 2
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 108010043652 Transketolase Proteins 0.000 claims description 2
- 239000003098 androgen Substances 0.000 claims description 2
- 230000003172 anti-dna Effects 0.000 claims description 2
- 210000004292 cytoskeleton Anatomy 0.000 claims description 2
- 102000005525 fibrillarin Human genes 0.000 claims description 2
- 108020002231 fibrillarin Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 108010017282 serpin B6 Proteins 0.000 claims description 2
- 108010022404 serum-glucocorticoid regulated kinase Proteins 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 210000001177 vas deferen Anatomy 0.000 claims description 2
- 102100036664 Adenosine deaminase Human genes 0.000 claims 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 238000000018 DNA microarray Methods 0.000 claims 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 1
- 102000011720 Lysophospholipase Human genes 0.000 claims 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims 1
- 102100033055 Transketolase Human genes 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 34
- 238000000370 laser capture micro-dissection Methods 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 210000000981 epithelium Anatomy 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 210000003405 ileum Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 230000035479 physiological effects, processes and functions Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 230000000378 dietary effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 102000055025 Adenosine deaminases Human genes 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 108010059881 Lactase Proteins 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 238000011785 NMRI mouse Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229940116108 lactase Drugs 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 230000036267 drug metabolism Effects 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003134 paneth cell Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000002153 concerted effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229920000768 polyamine Polymers 0.000 description 4
- 108010070701 procolipase Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 3
- 102000004031 Carboxy-Lyases Human genes 0.000 description 3
- 108090000489 Carboxy-Lyases Proteins 0.000 description 3
- 101100323232 Mus musculus Ang3 gene Proteins 0.000 description 3
- 101000780064 Mus musculus Angiogenin-2 Proteins 0.000 description 3
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 3
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 3
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004082 barrier epithelial cell Anatomy 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015816 nutrient absorption Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100038199 Desmoplakin Human genes 0.000 description 2
- 108091000074 Desmoplakin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102100037883 Phospholipase B1, membrane-associated Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000000495 immunoinflammatory effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 210000002011 intestinal secretion Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 238000002966 oligonucleotide array Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007542 postnatal development Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- 230000022814 xenobiotic metabolic process Effects 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000945470 Arcturus Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000304137 Bacteroides thetaiotaomicron VPI-5482 Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 208000035984 Colonic Polyps Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101710117072 Dual specificity protein phosphatase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 101100481715 Escherichia phage N15 gene 16 gene Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
- 206010051635 Gastrointestinal tract adenoma Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000034575 Glutamate transporters Human genes 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 101150060239 MOM1 gene Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000011279 Multidrug resistance protein 1 Human genes 0.000 description 1
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 1
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000757201 Mus musculus Angiogenin-4 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150095279 PIGR gene Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000003753 Plakophilins Human genes 0.000 description 1
- 108010057275 Plakophilins Proteins 0.000 description 1
- 102100030477 Plectin Human genes 0.000 description 1
- 108010054050 Plectin Proteins 0.000 description 1
- 102100037394 Proline-rich nuclear receptor coactivator 1 Human genes 0.000 description 1
- 101710162929 Proline-rich nuclear receptor coactivator 1 Proteins 0.000 description 1
- 101710124297 Proline-rich protein 2 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010005730 R-SNARE Proteins Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 102000002215 Synaptobrevin Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010007389 Trefoil Factors Proteins 0.000 description 1
- 102000007641 Trefoil Factors Human genes 0.000 description 1
- 101000955470 Trichophyton rubrum (strain ATCC MYA-4607 / CBS 118892) ABC multidrug transporter MDR5 Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000054078 gamma Catenin Human genes 0.000 description 1
- 108010084448 gamma Catenin Proteins 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000001362 glutamatergic neuron Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000010243 gut motility Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000012256 transgenic experiment Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to methods for investigating changes resulting from commensal microflora colonisation of mammalian intestine, and the use of information obtained in the production of agents and therapies useful in the modification of the digestive tract and in the treatment of gastrointestinal- associated disease.
- Mammals generally and humans in particular are home to an incredibly complex and abundant ensemble of microbes. Contact with components of this microflora begin at birth.
- the human intestine is more densely populated with microbes than any other mucosal surface. Therefore, this organ represents a site where the microflora are likely to have a pronounced influence on host physiology.
- a method of investigating changes resulting from commensal microflora colonisation of mammalian intestine which comprises : a) measuring gene expression in commensal bacterium-colonized and germ-free intestine of at least one gene; and b) identifying a gene from a) that has at least a 2-fold difference in expression level between intestines colonised by at least one commensal bacterium and germ-free intestines.
- multiple gene expression is measured by DNA icroarray analysis and/or quantitative RT-PCR as illustrated hereinafter, but other conventional methods may be applied. Examples of such methods include quantitative Northern blotting as well as Representational Differentiation Analysis (RDA) which is a PCR based assay which detects genes that differ between two samples (e.g., Odeberg J, et al . , Biomol. Eng. 17, 1-9, 2000).
- RDA Representational Differentiation Analysis
- the use of high-density oligonucleotide arrays is preferred for conducting a comprehensive analysis of the range of intestinal functions that are shaped by components of the microflora.
- Microarray analysis can be used to measure host responses in a complex tissue composed of multiple cell types, as is found in the intestine.
- the value. of an in vivo model for delineating host cellular responses to a given microbe is that, unlike cell culture-based models, the contributions of lineage and environmental factors to shaping the response are preserved, and may be studied in a germfree experimental system.
- the responding cell population is recovered without perturbing its expressed mRNA population, so that its reaction to the microbe can be characterized in quantitative terms . This is suitably achieved by combining two techniques, laser-capture microdissection (LCM) , followed by quantitative analysis for example quantitative PCR and/or microarray analysis of the laser-capture samples.
- LCM laser-capture microdissection
- the germ-free intestine and the commensal bacterium- colonized intestine used in the method of the invention may be in any animal model, but in particular a simplified mouse model of intestinal-microbial interactions is used.
- Genes identified in this way and their function may then be subject to further study in order to determine their effects, for example on the digestive process.
- the further investigation may be carried out in for example using any of the conventional methods .
- the method further comprises (c) the step of further investigating a gene identified in b) with regard to its function.
- Suitable methods by which this can be achieved include work in in vitro cell culture assays or in lower eukaryotic model organisms as well as in animal models such as transgenic animal models.
- Lower eukaryotic model organisms such as yeast (e.g., Saccharomyces cerevisae) , the fruit fly (Drosophila melanogaster) and the ne atode (Caenorhbditis elegans) are eukaryotic organisms with very well defined genomes and in many instances cellular function.
- yeast e.g., Saccharomyces cerevisae
- the fruit fly Drosophila melanogaster
- the ne atode ne atode
- These organisms are easier to handle than mammals .
- the function can be studied using methods such as i) transgenic knockout; ii) dominant-negative experiments; iii) transgene overexpression; iv) antibody binding assay; v) by pharmacological intervention using defined chemical agents .
- Transgenic knockout methods are based upon inactivation of a gene within an organism, for example using recombinant DNA technology to delete or mutate a gene such that the gene product is dysfunctional, or to introduce an antisense oligonucleotide to silence the gene.
- antisense oligonucleotides which are complementary to the messenger RNA molecule (mRNA) of the gene are introduced in the organism.
- the messenger RNA molecule (mRNA) that is -the result of transcription of a gene is single stranded and can not be translated into a protein sequence if it is double stranded. Double stranded RNA is formed with the complementary fragment and the resulting double stranded RNA fragment can not be further processed.
- Classical transgenic knockout methods are based on introducing a mutated, and thereby dysfunctional gene into an embryonal cell line. This cell line is then introduced into a normal blastocyst, thereby creating a chimeric fetus consisting of germ cells from the normal background and from the embryonal stem (ES) cell line. Through several rounds of breeding the ES cell- derived mutant allele will be found in the germ cell and thus be transferable to offspring. New techniques now allow for such mutations to be inherited in a silent and inactive form, so that they can be activated in adult life when development is completed.
- the classical transgenic experiment involving transgene overexpression includes introducing a gene normally absent from the model (e.g., a human-specific gene into mouse) to assess the effects of the gene on cellular function and/or physiology. If required, the transgene may be placed under the control of tissue- specific promoter sequence so that expression is directed to a cell population of choice. Promoters exist both for a generalised expression throughout the body and for very subtle distribution in specific minor cell population in defined areas of an organ. Other means of studying the effects of genes involve intervention at the protein level with the gene product.
- antibody binding assays can be used both to determine whether a protein is present in a cell, model organism or mammal and/or to inhibit the function of the gene product by specifically binding to it and interfering with its capacity to interact with its intended molecular partners.
- Pharmacological intervention using defined chemical agents may be particularly useful if the gene can be identified as belonging to a specific class of molecules, e.g., G-protein coupled receptors, proteases or nuclear receptors, its functions can be assessed by using chemicals that are known to act as agonists or antagonists for this type of molecules.
- a specific class of molecules e.g., G-protein coupled receptors, proteases or nuclear receptors
- Any commensal bacteria may be used in the method of the invention.
- Particular examples include Bacteroides thetaiotaomicron, Escherischia coli , Bifidobacterium infant is, or mixtures thereof, or complete ileal and/or cecal microflora obtained from conventionally-raised species.
- a particularly suitable bacterium for use in the method is B. thetaiotaomicron .
- the applicants have found that different members of the commensal flora produce different results, indicating a high level of specificity amongst species.
- the method of the invention has already revealed an unanticipated breadth of this commensal's impact on gut gene expression.
- claim expression of a wide range of genes is measured in step (a) of the method of the invention.
- genes include genes associated with the nutrient uptake and metabolism, hormone/maturational responses, mucosal barrier function, detoxification/drug resistance, xenobiotic metabolism, motility, enteric nervous system/muscular layer development or activity, angiogenesis, cytos eleton/extracellular matrix function or development, signal transduction and other essential cellular functions .
- Nutrient uptake and metabolism genes which may be the subject of study include genes associated with carbohydrate uptake and metabolism such as Na+/glucose cotransporter (SGLTl) or lactase phlorizin-hydrolase genes, genes associated with lipid uptake and metabolism such as pancreatic lipase-related protein 2, colipase, liver fatty acid binding protein, fasting induced adipose factor (FIAF) , apolipoprotein A-IV, phospholipase B and CYP27 genes, metal uptake or sequestration genes such as high-affinity copper transporter, metallothionein I, metallothionein II or ferritin heavy chain genes, or cellular energy production such as isocitrate dehydrogenase subunit, succinyl CoA transferase, transketolase, malate oxidoreductase and aspartate aminotransferase genes.
- SGLTl Na+/glucose cotransporter
- genes associated with hormonal/maturational responses include adenosine deaminase, o ithine decarboxylase antizyme, 15-hydroxyprostaglandin dehydrogenase, GARG-16, FKBP51, androgen-regulated vas deferens protein, short chain dehydrogenase and heat-stable antigen genes.
- genes associated with mucosal barrier function include decay-accelerating factor, polymeric Ig receptor, small proline-rich protein 2a, serum amyloid A protein, CRP-ductin ⁇ (MUCLIN) , zeta proteasome chain, and anti-DNA IgG light chain genes .
- Suitable genes which are involved in detoxification/drug resistance include glutathione S-transferase, P-glycoprotein (mdrla) and CYP2D2 genes.
- genes associated with enteric nervous system/muscular layer development or activity include L-glutamate transporter, L-glutamate decarboxylase, vesicle-associated protein- 33, cysteine-rich protein 2, smooth muscle (enteric) gamma actin and SM-20 genes.
- RNAse super family members include several angiogenins . They also include the angiogenin-4, which the applicants have sequenced and found to be particularly interesting in that it is intestine- specific, epithelial-based and its expression appears to be regulated by components of the microbiota.
- the sequence of murine angiogenin-4 has recently been published (D.E. Holloway et al . , Protein Expression and Purification, (2001), 22:307. The applicants have surprisingly found that one such gene, specifically the angiogenin-4 gene is expressed in intestinal epithelium and that expression levels are particularly affected by commensal bacteria.
- genes associated with cytoskeleton/extracellular matrix function include gelsolin, destrin, alpha cardiac actin, endoB cytokeratin, fibronectin, proteinase inhibitor 6 and alpha 1 type 1 collagen genes .
- Signal transduction genes include Pten, gplO ⁇ (TB2/DP1) , rac2, Semcap2, serum and glucocorticoid-regulated kinase, STE20- like protein kinase and B-cell myeloid kinase.
- the signal pathway in which rac2 gene is associated in known to have an impact on the mucosal barrier function
- genes associated with essential cellular functions include glutathione reductase, calmodulin, elF3 s ⁇ bunit, hsc70, oligosaccharyl transferase subunit, fibrillarin, HH—transporting ATPase and Msec23 genes.
- step (a) at least 10 such genes are measured in step (a) .
- expression of all the genes listed above are measured.
- genes with at least a 2- fold difference in expression are identified and selected for further study.
- genes for which at least a 4-fold difference, more suitably at least a 5-fold difference, yet more suitably a 7-fold difference and preferably a 9-fold difference in expression are identified in step (b) and are selected for further study.
- genes which have already been identified using the method of the invention following colonisation with B. thetaiotaomicron and are of particular interest include colipase, decay-accelerating factor (DAF) , the polymeric IgA receptor, small proline-rich protein 2a (Sprr2a) , ⁇ angiogenin-3, ⁇ Pten, CYP2D2, Sprr2a, rac2, and Mdr-1. They also include angiogenin-4, a newly discovered protein which is related to angiogenin-3.
- genes may have useful therapeutic functions and thus, the expression of one or more of these genes is preferably measured in the method of the invention in order to detect the impact of the particular commensal bacteria undergoing study on their expression.
- the method of the invention has found that expression of colipase and angiogenins such as the angiogenin whose gene is amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinafter) which is angiogenin-4, as well as Sprr2a and rac2 should be subject to further investigation.
- angiogenins such as the angiogenin whose gene is amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinafter) which is angiogenin-4, as well as Sprr2a and rac2 should be subject to further investigation.
- the invention further comprises evaluation of the biochemical pathway in which the angiogenin whose gene is amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinafter) which is angiogenin-4, participates in the intestine.
- the invention further comprises evaluation of the biochemical pathway in which colipase participates in the intestine.
- the invention further comprises evaluation of the biochemical pathway in which Sprr2a participates in the intestine.
- the invention further comprises evaluation of the biochemical pathway in which rac2 participates in the intestine. Evaluation can be carried out using any suitable method, including those described above.
- This may be effected by administration of an appropriate commensal bacteria.
- Increased populations of desirable microflora may be achieved by administration of the bacteria in oral form, such as in the form of tablets, pharmaceutical or nutriceutical compositions or even foodstuffs such as live yoghurt cultures
- the invention provides a method of modulating epithelialy-expressed angiogenesis factor by colonisation with a commensal bacteria which effects said modulation.
- Another particular example of such a methods is a method of modifying metabolism, in particular of dietary lipids, which method involves use of a commensal bacteria identified using a method as described above, as having an effect on said metabolism.
- Yet another particular example is a method of modifying epithelial barrier function using a commensal bacteria identified using the above-described method.
- Another example is a method of preventing or treating tumors of the intestine, by modifying the population of commensal bacteria present therein which bacteria have been identified using the method of the invention as modulating angiogenesis, or signal transduction .
- the method of the invention may be useful in diagnosis of disease or conditions caused by inappropriate levels of gene expression in the gut.
- Analysis of commensal microflora taken from a patient will show a high degree of natural variation in the populations of microflora as discussed above.
- the detection of particularly elevated or reduced levels of commensal microflora identified using the method of the invention may indicate that a particular gene is being expressed at abnormal levels, giving rise to a disease state or condition.
- Treatment of such conditions may be effected either by altering the levels of the commensal bacteria as appropriate and as discussed above, or by direct administration of a bacterial or human gene product or derivative, or of means to block the gene product at the protein level, such as using chemical or biological inhibitors or antagonists of the gene product.
- the method of the invention can be used widely to address a question that applies to humans and innumerable other species that reside in our microbe-dominated world, namely how do bacteria contribute to and regulate the physiology and maturation of their hosts?
- assembly and maintenance of a microflora undoubtedly involves intricate combinatorial regulatory mechanisms, developed over the course of a long selective process that involved co-evolution of our predecessors with their microbial partners.
- the results presented below demonstrate the impact of an indigenous bacterial species on expression of genes that participate in vital physiologic functions, and emphasize the importance of viewing our biology as intertwined with the biology of our complex assemblies of resident bacteria.
- results demonstrate the practicality of using defined in vivo models to deduce the responses of specified cellular populations within complex tissues to microbes, in a manner that preserves the influence of the surrounding cellular and environmental milieu.
- the method has already revealed that a number of genes or gene products appear to have a significant effects in intestinal tissue, giving rise to the possibility that pharmaceuticals could be developed to target such genes or gene products in a manner which is beneficial to a patient. This can be done by screening for compounds which modulate the activity of the gene product .
- a further aspect of the invention comprises a method for identifying genes that function as regulators of intestinal biology, said method comprising applying the method as described above and detecting expression genes which have not heretofore been associated with such function.
- a further aspect of the invention comprises a method of screening compounds having a pharmaceutical application in a gastrointestinal disease, which method comprises assaying the compounds for their ability to modulate the activity of the product of a gene identified using a method described above.
- Yet a further aspect of the invention is a method of treating or preventing gastrointestinal disease which method comprises administering a therapeutically effective amount of a compound which modulates the activity of the product of a gene identified using a method according to claim 1.
- the invention further provides a method of screening for a compound potentially useful for treatment or prophylaxis of conditions characterized by a defect in intestinal barrier function which comprises assay of the compound for its ability to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2.
- a defect in intestinal barrier function comprises assay of the compound for its ability to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2.
- the compounds are useful in the treatment or prophylaxis of conditions in which intestinal barrier function is comprised.
- a further aspect of the invention comprises the use of a compound able to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2 in preparation of a medicament for the treatment or prophylaxis of conditions characterized by a defect in intestinal barrier function.
- small proline-rich protein 2a sprr2a
- rac2 small proline-rich protein 2a
- the compounds will be formulated as pharmaceutical compositions.
- Novel compositions of this type and their preparation form a further aspect of the invention.
- Figure 2 shows the results of real-time quantitative RT-PCR analyses of mRNA levels in isolated from laser-captured cell populations. Values are expressed relative to levels in germ-free mesenchyme using ⁇ CT analysis described below. Each gene product per sample was assayed in triplicate in 3-4 independent experiments. Representative results (mean ⁇ 1 S.D.) from pairs of germ-free and colonized mice are plotted.
- FIG. 3 shows the results of an experiment to illustrate the specificity of host responses to colonization with different members of the microflora.
- Germ-free mice were inoculated with one of the indicated organisms, or with a complete ileal/cecal flora from conventionally raised mice (Conv. microflora) ( 4) .
- Figure 4 shows the nucleotide sequences of mouse angiogenin-4 and angiogenin-3 in alignment (SEQ ID NOS 29 and 30 respectively) .
- Figure 5 illustrates the sequence alignment of the amino acid sequences of mouse angiogenin family members (SEQ ID NOS 31-34) .
- Figure 6 shows the locations of primers specific for mouse angiogenin family members .
- Figure 7 is a graph illustrating tissue distribution of angiogenin-4 mRNA, together with the results of an agarose gel analysis .
- Figure 8 is a graph illustrating tissue distribution of angiogenin-1 mRNA.
- Figure 9 is a graph illustrating tissue distribution of angiogenin-3 mRNA following quantitative real-time RT-PCR analysis.
- Figure 10 shows the results of RT-PCR analysis showing the absence of angiogenin-related protein expression.
- Figure 11 is a set of graphs showing the results of experiments on the microbial regulation of angiogenin-4 expression in the small intestine.
- Figure 12 is a graph showing the regulation of angiogenin-4 expression during postnatal development.
- Figure 13 is a block graph showing cellular localization of angiogenin-4 expression in small intestine: qRT-PCR analysis of cells isolated from the crypt base.
- mice In order to study at a molecular level, the changes in the intestine orchestrated by commensal bacteria, germ-free mice were colonised with commensal bacteria including Bacteroides thetaiotaomicron, a prominent component of the normal mouse and human intestinal microflora.
- B. thetaiotaomicron normally colonizes the distal small intestine (ileum) during the suckling-weaning transition, a time of rapid and pronounced functional maturation of the gut (W. E. C. Moore, L. V. Holdeman, Appl . Microbiol . 27, 961 (1974), T. Ushijima, M. Takahashi, K. Tatewaki, Y. Ozaki, Microbiol . Immunol . 27, 985 (1983) ) .
- Colonization elicited a concerted response involving enhanced expression of four components of the host's lipid absorption machinery.
- mRNAs encoding pancreatic lipase related protein-2 (PLRP-2) and colipase increased an average of 4- and 9- fold, respectively (Tables 1 and 2) .
- PLRP-2 hydrolyzes tri- and diacylglycerols, phospholipids and galactolipids .
- Colipase augments PLRP-2 activity (M. E. Lowe, M. H. Kaplan, L. Jackson- Grusby, D. D'Agostino, M. J. Grusby, J. Biol . Chem. 273, 31215 (1998) ) .
- L-FABP mRNA which encodes an abundant cytosolic protein involved in fatty acid trafficking within enterocytes, and an induction of apolipoprotein AIV, a prominent component of triglyceride-rich lipoproteins (chylomicrons, VLDL) secreted from the basolateral surfaces of enterocytes (Table 1) .
- B . thetaiotaomicron elicits an increased host capacity for nutrient absorption/processing and may provide a partial explanation as to why germ-free rodents require a higher caloric intake to maintain their weight than those with a normal microflora (B. S. ostmann, C. Larkin, A. Moriarty, E. Bruckner- Kardoss, Lab. Anim. Sci . 33, 46 (1983) .
- colonisation produces changes in expression of four genes involved in dietary metal absorption.
- a high affinity epithelial copper transporter (CRT1) mRNA was increased, while metallothionein-I, metallothionein-II, and ferritin heavy chain mRNAs were decreased (Table 1) .
- CRT1 epithelial copper transporter
- metallothionein-I, metallothionein-II, and ferritin heavy chain mRNAs were decreased (Table 1) .
- Colipase plays a critical role in dietary lipid metabolism by stimulating the activity of both pancreatic triglyceride lipase and PLRP-2. Furthermore, proteolytic cleavage of procolipase yields a pentapeptide (enterostatin) that functions as a satiety signal for fat ingestion (S. Okada, D. A. York, G. A. Bray, Physiol . Behav. 49, 1185 (1991)).
- entertatin pentapeptide
- the significantly elevated expression found following colonisation with B. thetoaiotaomicron illustrated hereinafter are indicative of a previously unappreciated mechanism by which the intestinal epithelium, together with a resident gut bacterium, contributes to dietary lipid metabolism.
- DAF decay accelerating factor
- Colonization did not produce a notable change (i.e. two fold or more) , in the expression of genes encoding other proteins linked to desmosomes (desmoplakin, plakoglobin, plakophilin, plectin) , or tight junctions (ZO-1, occludin) .
- Sprr2a expression in the intestine and its microbial regulation are novel findings.
- the critical contribution of sprr2a to the squamous epithelial barrier and the dramatic response of sprr2a expression to B . thetaiotaomicron together suggest that this protein plays an important role in intestinal barrier function. It is therefore a particularly suitable target for further investigation in accordance with the invention, in particular by evaluating the biochemical pathway in which Sprr2a participates in the intestine.
- LPH lactase-phlorizin hydrolase
- enterocytic brush-border enzyme that hydrolyzes the principal milk sugar, lactose.
- LPH mRNA levels rise throughout the small intestine of conventionally raised animals during the suckling period, and then fall in the ileum during weaning (S. D. Krasinski et al . , Am. J. Physiol . 267, G584 (1994) ) .
- the effects of commensal bacteria on expression of these genes in particular may be of interest in determining whether the bacteria have signficant impact.
- colonization results in increased expression of angiogenin-4 which resembles angiogenin-3, a secreted protein with demonstrated angiogenic activity (X. Fu, et al . , Mol . Cell Biol . 17, 1503 (1997), X. Fu, et al . , Growth Factors 17, 125 (1999)).
- the 11-fold increase in expression of the angiogenesis factor recognizable by amplification using primers of SEQ ID NO 12 and SEQ ID NO 25, which is angiogenin-4 (Table 1,2) upon B .
- thetaiotaomicron colonization represents a novel mode of regulation for an angiogenesis factor and so may be the subject of further investigation in accordance with the invention.
- Pten is a member of a family of dual specificity protein phosphatases. PTEN haploinsufficiency in humans is associated with increased susceptibility to tumorigenesis (D. J. Marsh et al., Hum. Mol . Genet . 7, 507 (1998)). Furthermore,- Pten+/-**Pten+/+ chimeric mice develop colonic polyps and adenocarcinoma (A. DiCristofano, B. Pesce, C. Cordon-Cardo, P. P. Pandolfi, Na t . Genet . 19, 348 (1998)).
- the human homolog of Gpl06, TB2/DP1 is a component of a locus which when mutated produces multiple intestinal adenomas (R. W. Burt, Adv. Exp. Med. Biol . 470, 99 (1999) ) .
- the finding that a component of the microflora affects expression of genes such as the angiogenesis factor whose gene is amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinafter) which is angiogenin-4, Pten and Gpl06 highlights the importance of considering mechanisms by which intestinal bacteria may contribute to the initiation or progression of tumorigenesis within, or even outside, the gut.
- the motility of the intestine is regulated by its enteric nervous system (ENS) .
- ENS enteric nervous system
- the relative contributions of intrinsic and extrinsic factors to ENS activity are poorly understood, despite the fact that irritable bowel syndrome, which involves dysregulated motor activity, is a major health problem.
- commensal bacteria such as B. thetaiotaomicron on gut physiology extends to genes expressed in the enteric nervous system (ENS) and in the muscular layers.
- mRNAs encoding the L- glutamate transporter and L-glutamate decarboxylase, which converts glutamate to GABA, are both increased, suggesting a colonization-associated effect on the glutamatergic neurons of the ENS (M. T. Liu, J. D. Rothstein, M.
- thetaiotaomicron normally colonizes mouse and human intestine during weaning (W. E. C. Moore, L. V. Holdeman, Appl . Microbiol . 27, 961 (1974), T. Ushiji a, M. Takahashi, K. Tatewaki, Y. Ozaki, Microbiol . Immunol . 27, 985 (1983)).
- This period is characterized by a dramatic shift in the composition of the microflora and by a series of critical developmental changes in the intestinal epithelium. It is unclear how many of these changes are regulated by intrinsic cellular mechanisms, and how many are controlled by extrinsic signals emanating from the mesenchyme, or from luminal (dietary, microbial) factors.
- B. thetaiotaomicron colonization produces an increase in mRNAs encoding ADA and ornithine decarboxylase (ODC) antizyme but not a 5-fold increase.
- ODC ornithine decarboxylase
- a further aspect of the invention provides a protein of SEQ ID NO 29 as shown in Figure 4 hereinafter, or an allelic variant thereof or a protein which has at least 85% amino acid sequence identity with SEQ ID NO 29.
- the invention provides a protein of SEQ ID NO 29.
- the invention provides a nucleic acid which encodes a protein as described above.
- Example 1 illustrates the invention.
- mice Age-matched groups of 7-15 week-old germ-free NMRI/KI mice were maintained in plastic gnotobiotic isolators on a 12hour light cycle, and given free access to an autoclaved chow diet (B&K Universal) . Males were inoculated with wild-type B. thetaiotaomicron (strain VPI-5482) (L. Hooper et al (1999) supra) . Mice were sacrificed 10 days later, 2hours after lights were turned on. The distal 1 cm of the small intestine was used to define the number of colony forming units per ml of extruded luminal contents .
- AGG liver fatty acid binding protein (L- 5'- CTCCGGCAAGTACCAATTGC 5'- TGTCCTTCCCTTTCTGGATGAG 16
- FABP metallothionein I (MT-I) -, 5'- ATGTGCCCAGGGCTGTGT 4 5'- AACAGGGTGGAACTGTATAGGA 17
- pigR decay accelerating factor
- adenosine dearninase (ADA) 5'- GCGCAGTAAAGAATGGCATTC 11 5'- CTGTCTTGAGGATGTCCACAGC 24 angiogenin-4 5*- TCGATTCCAGGTCACCACTTG 12 5'- CACAGGCAATAACAATATATCT 25 o o GAAATCT glyceraldehyde 3 -phosphate 5'- TGGCAAAGTGGAGATTGTTGCC 13 5'- AAGATGGTGATGGGCTTCCCG 26 dehydrogenase
- transcripts represented by 95 probe-sets were increased, while those represented by 23 probe-sets were decreased.
- the genes represented by 84 of these probe sets were assigned to functional groups and these are set out in Table 1 hereinafter. In this table, results are presented as the fold-difference in mRNA levels between colonized and germ-free ileum and represent average values from duplicate microarray hybridizations. The average fold-changes for genes represented by 2 or more independent probe sets are listed separately.
- genes which were found to have a difference in expression levels of 5-fold or more as a result of B. thetaiotaomicron colonisiation were colipase, liver fatty acid binding protein, fasting-induced adipose factor, metallothionein I and metallothionein II, malate oxidoreductase, Sprr2a, angiogenin-3, angiogenin-related protein, angiogenin family, gelsolin, gpl06 (TB2/DP1) and rac 2.
- colipase, fasting-induced adipose factor, angiogenin 3 and Sprr2a genes showed a difference in expression levels of 9-fold or more.
- a notable feature of the host response to B. thetaiotaomicron was the absence of detectable or changed expression of the many genes involved in immuno-inflammatory processes that are represented on the microarrays . These include genes involved in the NF-KB-regulated processes that are critical regulators of host responses to invasive pathogens (D. Elewaut et al . , J. Immunol . 163, 1457 (1999)). The absence of these responses can be contrasted to results obtained in a recent cDNA microarray analysis of the response of a human intestinal epithelial cell line to Salmonella , an invasive gut pathogen (L. Eckmann, J. R. Smith, M. P. Housley, M. B. Dwinell, M. F.
- LCM laser-capture microdissection
- Colipase is produced by the exocrine (acinar) cells of the pancreas. Expression in the intestine had not been reported previously. Therefore, LCM and real-time RT-PCR analysis were employed to delineate the cellular origins of its response to B. thetaiotaomicron .
- proteolytic cleavage of procolipase yields a pentapeptide (enterostatin) that functions as a satiety signal for fat ingestion (S. Okada, et al . , Physiol . Behav. 49, 1185 (1991).
- Entertatin a pentapeptide that functions as a satiety signal for fat ingestion
- Angiogenin-3 was originally identified in NIH 3T3 fibroblasts (X. Fu et al., Mol . Cell Biol . 17, 1503 (1997), but little is known about its cellular origins or regulation. LCM and qRT-PCR revealed that the crypt epithelium is the predominant location of a gene amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinbefore) which are specific for angiogenin-3 mRNA, but also for the new protein which is angiogenin-4 mRNA and that colonization results in a 7-fold increase in its levels within this compartment. This increase accounts for the change in expression defined by microarray and qRT-PCR analyses of total ileal RNA (Tables 1,2).
- the epithelial location of a secreted/RNAse/angiogenesis factor puts it in a strategic position to function as an effector of a number of host responses to microbial colonization (e.g., enhanced absorption/distribution of nutrients/augmented barrier function.
- Example 2 The 11-fold induction of its mRNA seen in Example 1 was independently validated by real-time RT-PCR of total ileal RNAs (Table 2) .
- Angiogenin-3 was originally identified in NIH 3T3 fibroblasts (X. Fu, M. P. Kamps, Mol . Cell Biol . 17, 1503 (1997) ) .
- LCM and real-time RT-PCR analysis revealed that in colonized ileum, the levels of mRNA which are amplifiable using primers designed for angiogenin-3 are highest in crypt epithelium (values in the ileal villus epithelium and mesenchyme are 14- and 15-fold lower, respectively; Fig. 2) .
- this mRNA is in fact, angiogenin-4 mRNA.
- the 7-fold increase in these angiogenin-4 mRNA levels observed in the crypt epithelium after colonization account for the change defined by microarray and real-time RT-PCR analyses of total ileal RNA.
- Bacterial modulation of epithelially-expressed angiogenin-4 represents a novel mode of regulation for an angiogenesis factor.
- B. thetaiotaomicron strain VPI-5482 (L.V. Hooper, et al . , Proc. Na tl . Acad. Sci . U. S. A. 96, 9833 (1999)), (iii) E. coli K12 which was originally recovered from a normal human fecal flora, (iv) Bifidobacterium infantis (ATCC15697) , a prominent component of the pre-weaning human and mouse ileal flora and a commonly used probiotic.
- a further control group comprised mice conventionally raised since birth.
- mice were sacrificed lOdays later, 2hours after lights were turned on.
- the distal 1 cm of the small intestine was used to define CFU/ml ileal contents.
- the 3 cm of intestine just proximal to this segment was used to isolate total ileal RNA (Qiagen RNeasy kit) .
- the Mdrla/GST responses provide direct evidence that components of the normal microflora can modulate host genes involved in drug metabolism, and suggest that variations in drug metabolism between individuals may arise, in part, from differences in their resident gut flora.
- Example 4 Following the observation that a lOd colonization was associated with a 11-fold increase in ileal expression of a mRNA detected by an Affymetrix-designed probe-set designed from the published sequence of angiogenin-3, we designed primers specific for the 3' and 5' ends of the mouse angiogenin-3. There were:
- RNA prepared from the ileums of ex-germ- free NMRI mice had been colonized , for lOd with a complete ileal/cecal flora harvested from conventionally-raised animals belonging to the same inbred strain.
- the nucleotide sequence of the ORF was only 90% identical to that of mouse angiogenin-3. Since the primer sequences used in the PCR reaction (specific for angiogenin-3) were incorporated into the product, we used 5'- and 3' -RACE to (a) obtain accurate sequence at the 5' and 3' ends of the ORF of this new angiogenin, and (b) characterize the 5'- and 3'- untranslated regions of its mRNA. The results revealed only 88.3% nucleotide sequence identity with angiogenin-3 mRNA.
- the nucleotide sequence which encodes the angiogenin-4 protein, aligned with the angiogenin-3 sequence is shown hereinafter in Figure 4 as SEQ ID NO 29 and 30 respectively.
- - Angiogenin-4 has 74 to 81% amino acid sequence identity to the other 3 members of the mouse angiogenin family ( Figure 5) . It was found that the 5' and 3' -untranslated regions of angiogenin-4 are closely related to the corresponding regions of angiogenin-3 mRNA ( Figure 4) . Subsequently a comparative analysis of the tissue distribution of the various mouse angiogenin mRNAs, was conducted.
- cDNA was synthesized from RNAs isolated from tissues harvested from conventionally raised adult (12-14 week old) male and female NMRI mice (25 tissues/mouse) .
- primer sets specific for each of the four mouse angiogenin family members (Figure 6; Table 4) and used them for SYBR-Green-based real-time quantitative RT-PCR (qRT-PCR) analyses .
- angiogenin-4 mRNA was restricted the intestine where it is expressed from the duodenum to the rectum ( Figure 7) .
- angiogenin-1 expression is highest in liver, lung, and pancreas ( Figure 8)
- angiogenin-3 is expressed primarily in liver, lung, pancreas, and prostate ( Figure 9) .
- Angiogenin-related protein mRNA was undetectable in all tissues surveyed even after 40 cycles of PCR ( Figure 10) .
- angiogenin-4-specific primers and qRT-PCR were used to compare angiogenin-4 mRNA levels along the length of the small intestine of germ-free NMRI mice and germ-free mice colonized for 10 d with an ileal/cecal flora harvested from conventionally raised NMRI animals. Pair-wise comparisons revealed that expression of angiogenin-4 is highest in the jejunum of colonized mice, and that conventionalization induces up to a 17-fold increase in angiogenin-4 expression in this region ( Figure 11) . Mono-association of germ-free NMRI mice with B. thetaiotaomicron for lOd resulted in a comparable induction of angiogenin-4 expression (data not shown) .
- angiogenin-3 forward 37 5' CTGGCTCAGGATAACTACAGGTACAT reverse 38 5' GCCTGGGAGACCCTCCTTT angiogenin- 1 forward 39 5' AGCGAATGGAAGCCCTTACA reverse 40 5' CTCATCGAAGTGGACCGGCA
- angiogenin- forward 41 5' GGTGAAAAGAAAGCTAACCTCTTTC related protein reverse 42 5' AGACTTGCTTATTCTTAAATTTCG
- Example 2 The previous laser capture microdissection (LCM) /qRT-PCR study of the cellular origins of angiogenin protein expression (Example 2) used primers that recognize both angiogenin-3 and angiogenin-4, and RNAs that had been isolated from captured crypt epithelium, villus epithelium, or mesenchymal populations from the villus core.
- the qRT-PCR analysis indicated that the icrobially-regulated angiogenin' was produced in epithelial cells located at the base of crypts of Lieberkuhn (Hooper et al., 2001) .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
a method of investigating chemical changes resulting from commensal microflora colonisation of mammalian intestine which comprises: a) measuring gene expression in commensal bacterium-colonized and germ-free intestine of at least one gene; and b) identifying a gene from a) that has at least a 2-fold difference in expression level between commensal bacterium-colonized and germ-free intestine. The method selects genes for further evaluation, and gives rise to the development of prophylactic treatments.
Description
METHOD FOR STUDYING THE EFFECTS OF COMMENSAL MICROFLORA ON MAMMALIAN INTESTINE AND TREATMENTS OF GASTROINTESTINAL-ASSOCIATED
DISEASE BASED THEREON
TECHNICAL FIELD
The present invention relates to methods for investigating changes resulting from commensal microflora colonisation of mammalian intestine, and the use of information obtained in the production of agents and therapies useful in the modification of the digestive tract and in the treatment of gastrointestinal- associated disease.
BACKGROUND ART
Mammals generally and humans in particular are home to an incredibly complex and abundant ensemble of microbes. Contact with components of this microflora begin at birth. The human intestine is more densely populated with microbes than any other mucosal surface. Therefore, this organ represents a site where the microflora are likely to have a pronounced influence on host physiology.
Although the effects of pathogenic or other potentially harmful invasive microorganisms have been studied (see for example L. Eckmann et al . , J. Biol . Chem. 2000, 275:14084-14094, D. A. Relman, Science, 1999 May 21: 284 (5418) 1308-10, D.A. Relman, Curr. Opin.. Immunol. 2000 Apr : 12 (2) :215-8) astonishingly little is known about how commensal bacteria shape normal development and physiology. This is due partly to a paucity of defined, experimentally tractable in vivo model systems for examining how nonpathogenic microorganisms regulate host biology, but also to a prevailing view that these microorganisms had no significant impact on for instance the digestive processes.
A model using adult germ-free animals, colonized with Bacteroides thetaiotaomicron, has previously been used to show that this commensal organism regulates production of ileal epithelial fucosylated glycans after it is introduced into germ-
free mice, and to delineate how the microbe controls production of these glycans for its own nutritional benefit (L. Bry, et al., Science 273, 1380, 1996; L. V. Hooper, et al., Proc. Natl . Acad. Sci . USA 96, 9833 (1999) . Virtually nothing else is known about how indigenous bacteria modulate intestinal gene expression and how this impact on the host's condition.
The applicants have found that commensal microflora make significant contributions to defining gut physiology and maturation and have developed means for testing this at a molecular level.
SUMMARY OF THE INVENTION
According to a first aspect of the present invention there is provided a method of investigating changes resulting from commensal microflora colonisation of mammalian intestine which comprises : a) measuring gene expression in commensal bacterium-colonized and germ-free intestine of at least one gene; and b) identifying a gene from a) that has at least a 2-fold difference in expression level between intestines colonised by at least one commensal bacterium and germ-free intestines.
Suitably, multiple gene expression is measured by DNA icroarray analysis and/or quantitative RT-PCR as illustrated hereinafter, but other conventional methods may be applied. Examples of such methods include quantitative Northern blotting as well as Representational Differentiation Analysis (RDA) which is a PCR based assay which detects genes that differ between two samples (e.g., Odeberg J, et al . , Biomol. Eng. 17, 1-9, 2000). In particular, the use of high-density oligonucleotide arrays is preferred for conducting a comprehensive analysis of the range of intestinal functions that are shaped by components of the microflora.
Microarray analysis can be used to measure host responses in a complex tissue composed of multiple cell types, as is found in the intestine. The value. of an in vivo model for delineating host
cellular responses to a given microbe is that, unlike cell culture-based models, the contributions of lineage and environmental factors to shaping the response are preserved, and may be studied in a germfree experimental system. In a preferred embodiment, the responding cell population is recovered without perturbing its expressed mRNA population, so that its reaction to the microbe can be characterized in quantitative terms . This is suitably achieved by combining two techniques, laser-capture microdissection (LCM) , followed by quantitative analysis for example quantitative PCR and/or microarray analysis of the laser-capture samples.
Using the method of the invention, it is possible to establish the feasibility of assigning an in vivo host response to a particular cell population in a complex tissue, and describing that cellular response in quantitative terms. It may be possible to identify host genes that function as vital but heretofore unappreciated regulators of intestinal biology and host physiology. Genes identified based on their response to colonization by the prototypic gut commensal may represent entirely new targets for therapeutic manipulation. Intestinal microbes have been subjected to great selective pressure over millions of years to find subtle but effective ways of manipulating their host so that both microbe and host benefit from the relationship. Identifying and testing bacterial gene products that affect their host gene targets may yield new pharmacologic agents whose chemical structures and mechanisms of action would, or could not have been appreciated previously.
The germ-free intestine and the commensal bacterium- colonized intestine used in the method of the invention may be in any animal model, but in particular a simplified mouse model of intestinal-microbial interactions is used.
This method allows the effects of individual commensal bacteria to be studied, as well as combinations of these if required. The applicants have found that genes involved or implicated
in the immuno-inflammatory process are not likely to be identified using the method of the invention. This is consistent with the host's need to accommodate resident gut microbes, such as B. thetaiotaomicron , for its entire lifespan. The method of the invention however, can be used to confirm this finding with other commensural bacteria.
Genes identified in this way and their function may then be subject to further study in order to determine their effects, for example on the digestive process. The further investigation may be carried out in for example using any of the conventional methods .
In a preferred embodiment, the method further comprises (c) the step of further investigating a gene identified in b) with regard to its function. Suitable methods by which this can be achieved include work in in vitro cell culture assays or in lower eukaryotic model organisms as well as in animal models such as transgenic animal models.
In vitro cell culture assay techniques will allow studies in a less complex system than the whole animal' here the gene and its associated genes and gene products are available for manipulation and analysis.
Lower eukaryotic model organisms such as yeast (e.g., Saccharomyces cerevisae) , the fruit fly (Drosophila melanogaster) and the ne atode (Caenorhbditis elegans) are eukaryotic organisms with very well defined genomes and in many instances cellular function. Several of the basic signaling functions of interest to study in mammals are conserved also in the simpler eukaryotic life forms which makes them very attractive as models for defined molecular events . These organisms are easier to handle than mammals .
In these systems, the function can be studied using methods such as i) transgenic knockout; ii) dominant-negative experiments; iii) transgene overexpression;
iv) antibody binding assay; v) by pharmacological intervention using defined chemical agents .
Transgenic knockout methods are based upon inactivation of a gene within an organism, for example using recombinant DNA technology to delete or mutate a gene such that the gene product is dysfunctional, or to introduce an antisense oligonucleotide to silence the gene. In the latter case, antisense oligonucleotides which are complementary to the messenger RNA molecule (mRNA) of the gene are introduced in the organism. The messenger RNA molecule (mRNA) that is -the result of transcription of a gene is single stranded and can not be translated into a protein sequence if it is double stranded. Double stranded RNA is formed with the complementary fragment and the resulting double stranded RNA fragment can not be further processed. Thus no protein will be generated from this gene. This is usually done as a transient experiment, i.e., the antisense fragment is added to the cell, model organisms or mammalian model and the gene expression will be silenced as long as there is antisense available. After it is consumed, normal function will be resumed and the normal/control state will be reestablished.
Classical transgenic knockout methods are based on introducing a mutated, and thereby dysfunctional gene into an embryonal cell line. This cell line is then introduced into a normal blastocyst, thereby creating a chimeric fetus consisting of germ cells from the normal background and from the embryonal stem (ES) cell line. Through several rounds of breeding the ES cell- derived mutant allele will be found in the germ cell and thus be transferable to offspring. New techniques now allow for such mutations to be inherited in a silent and inactive form, so that they can be activated in adult life when development is completed. This is achieved by exposing the adult animal, in particular a mouse, carrying such a silent mutation to a chemical agent (hormone, antibiotic) that will activate expression of the mutated gene.
Another way of achieving a disruption of a gene function is by performing a dominant-negative experiment. In this cade a gene that is defective is introduced into the genome of the model organism under transcriptional control of a promotor that will allow very high expression in the targeted cell lineage. The product will by produced and transported to the intended site of action in the cell and compete with the normal gene product for these sites. As the transgene is present in higher amounts and is incapable of performing the intended function, the net outcome will be that this function is perturbed.
The effects of overexpression of the gene in a particular system or model may also be studied. In this case, either multiple gene copies may be introduced into the test organism or use can be made of particular promoters which express genes at high levels.
The classical transgenic experiment involving transgene overexpression includes introducing a gene normally absent from the model (e.g., a human-specific gene into mouse) to assess the effects of the gene on cellular function and/or physiology. If required, the transgene may be placed under the control of tissue- specific promoter sequence so that expression is directed to a cell population of choice. Promoters exist both for a generalised expression throughout the body and for very subtle distribution in specific minor cell population in defined areas of an organ. Other means of studying the effects of genes involve intervention at the protein level with the gene product. For example, antibody binding assays can be used both to determine whether a protein is present in a cell, model organism or mammal and/or to inhibit the function of the gene product by specifically binding to it and interfering with its capacity to interact with its intended molecular partners.
Pharmacological intervention using defined chemical agents may be particularly useful if the gene can be identified as belonging to a specific class of molecules, e.g., G-protein coupled receptors, proteases or nuclear receptors, its functions
can be assessed by using chemicals that are known to act as agonists or antagonists for this type of molecules.
Any commensal bacteria may be used in the method of the invention. Particular examples include Bacteroides thetaiotaomicron, Escherischia coli , Bifidobacterium infant is, or mixtures thereof, or complete ileal and/or cecal microflora obtained from conventionally-raised species. A particularly suitable bacterium for use in the method is B. thetaiotaomicron . The applicants have found that different members of the commensal flora produce different results, indicating a high level of specificity amongst species.
The method of the invention has already revealed an unanticipated breadth of this commensal's impact on gut gene expression. Suitably claim expression of a wide range of genes is measured in step (a) of the method of the invention. Examples of such genes include genes associated with the nutrient uptake and metabolism, hormone/maturational responses, mucosal barrier function, detoxification/drug resistance, xenobiotic metabolism, motility, enteric nervous system/muscular layer development or activity, angiogenesis, cytos eleton/extracellular matrix function or development, signal transduction and other essential cellular functions .
Nutrient uptake and metabolism genes which may be the subject of study include genes associated with carbohydrate uptake and metabolism such as Na+/glucose cotransporter (SGLTl) or lactase phlorizin-hydrolase genes, genes associated with lipid uptake and metabolism such as pancreatic lipase-related protein 2, colipase, liver fatty acid binding protein, fasting induced adipose factor (FIAF) , apolipoprotein A-IV, phospholipase B and CYP27 genes, metal uptake or sequestration genes such as high-affinity copper transporter, metallothionein I, metallothionein II or ferritin heavy chain genes, or cellular energy production such as isocitrate dehydrogenase subunit, succinyl CoA transferase, transketolase, malate oxidoreductase and aspartate aminotransferase genes. Examples of genes associated with hormonal/maturational
responses include adenosine deaminase, o ithine decarboxylase antizyme, 15-hydroxyprostaglandin dehydrogenase, GARG-16, FKBP51, androgen-regulated vas deferens protein, short chain dehydrogenase and heat-stable antigen genes. Examples of genes associated with mucosal barrier function include decay-accelerating factor, polymeric Ig receptor, small proline-rich protein 2a, serum amyloid A protein, CRP-ductinα (MUCLIN) , zeta proteasome chain, and anti-DNA IgG light chain genes . Suitable genes which are involved in detoxification/drug resistance include glutathione S-transferase, P-glycoprotein (mdrla) and CYP2D2 genes.
Examples of genes associated with enteric nervous system/muscular layer development or activity include L-glutamate transporter, L-glutamate decarboxylase, vesicle-associated protein- 33, cysteine-rich protein 2, smooth muscle (enteric) gamma actin and SM-20 genes.
RNAse super family members include several angiogenins . They also include the angiogenin-4, which the applicants have sequenced and found to be particularly interesting in that it is intestine- specific, epithelial-based and its expression appears to be regulated by components of the microbiota. The sequence of murine angiogenin-4 has recently been published (D.E. Holloway et al . , Protein Expression and Purification, (2001), 22:307. The applicants have surprisingly found that one such gene, specifically the angiogenin-4 gene is expressed in intestinal epithelium and that expression levels are particularly affected by commensal bacteria.
Examples of genes associated with cytoskeleton/extracellular matrix function include gelsolin, destrin, alpha cardiac actin, endoB cytokeratin, fibronectin, proteinase inhibitor 6 and alpha 1 type 1 collagen genes .
Signal transduction genes include Pten, gplOβ (TB2/DP1) ,
rac2, Semcap2, serum and glucocorticoid-regulated kinase, STE20- like protein kinase and B-cell myeloid kinase. (The signal pathway in which rac2 gene is associated in known to have an impact on the mucosal barrier function) . Finally, other examples of genes associated with essential cellular functions include glutathione reductase, calmodulin, elF3 sύbunit, hsc70, oligosaccharyl transferase subunit, fibrillarin, HH—transporting ATPase and Msec23 genes.
Suitably in the method of the invention, at least 10 such genes are measured in step (a) . Preferably, expression of all the genes listed above are measured.
In accordance with the invention, genes with at least a 2- fold difference in expression are identified and selected for further study. Suitably, genes for which at least a 4-fold difference, more suitably at least a 5-fold difference, yet more suitably a 7-fold difference and preferably a 9-fold difference in expression are identified in step (b) and are selected for further study.
Some particular genes which have already been identified using the method of the invention following colonisation with B. thetaiotaomicron and are of particular interest. These include colipase, decay-accelerating factor (DAF) , the polymeric IgA receptor, small proline-rich protein 2a (Sprr2a) , {angiogenin-3, } Pten, CYP2D2, Sprr2a, rac2, and Mdr-1. They also include angiogenin-4, a newly discovered protein which is related to angiogenin-3.
These genes may have useful therapeutic functions and thus, the expression of one or more of these genes is preferably measured in the method of the invention in order to detect the impact of the particular commensal bacteria undergoing study on their expression.
In particular, the method of the invention has found that expression of colipase and angiogenins such as the angiogenin whose gene is amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinafter) which is angiogenin-4, as well as
Sprr2a and rac2 should be subject to further investigation.
Thus, the invention further comprises evaluation of the biochemical pathway in which the angiogenin whose gene is amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinafter) which is angiogenin-4, participates in the intestine.
In an alternative embodiment, the invention further comprises evaluation of the biochemical pathway in which colipase participates in the intestine.
In an alternative embodiment, the invention further comprises evaluation of the biochemical pathway in which Sprr2a participates in the intestine.
In an alternative embodiment, the invention further comprises evaluation of the biochemical pathway in which rac2 participates in the intestine. Evaluation can be carried out using any suitable method, including those described above.
Identification of genes using the method of the invention as well as further .study of the biochemical pathways associated with these, could lead to prophylactic or therapeutic treatment of disease or disorders of the gastrointestinal tract. In particular, by identifying which genes are most affected by the presence or absence of commensal bacteria and which are involved in a biochemical pathway associated with a condition, disease or disorder, it would be possible to devise treatments aimed at altering expression of a particular gene in order to rectify that condition, disease or disorder. Alternatively, it would be possible to intervene pharmacologically in the pathways maintained by the gene products.
This may be effected by administration of an appropriate commensal bacteria. Increased populations of desirable microflora may be achieved by administration of the bacteria in oral form, such as in the form of tablets, pharmaceutical or nutriceutical compositions or even foodstuffs such as live yoghurt cultures
In particular, the invention provides a method of modulating epithelialy-expressed angiogenesis factor by colonisation with a
commensal bacteria which effects said modulation.
Another particular example of such a methods is a method of modifying metabolism, in particular of dietary lipids, which method involves use of a commensal bacteria identified using a method as described above, as having an effect on said metabolism. Yet another particular example is a method of modifying epithelial barrier function using a commensal bacteria identified using the above-described method.
Another example is a method of preventing or treating tumors of the intestine, by modifying the population of commensal bacteria present therein which bacteria have been identified using the method of the invention as modulating angiogenesis, or signal transduction .
In a further aspect, the method of the invention may be useful in diagnosis of disease or conditions caused by inappropriate levels of gene expression in the gut. Analysis of commensal microflora taken from a patient will show a high degree of natural variation in the populations of microflora as discussed above. However, the detection of particularly elevated or reduced levels of commensal microflora identified using the method of the invention may indicate that a particular gene is being expressed at abnormal levels, giving rise to a disease state or condition. Treatment of such conditions may be effected either by altering the levels of the commensal bacteria as appropriate and as discussed above, or by direct administration of a bacterial or human gene product or derivative, or of means to block the gene product at the protein level, such as using chemical or biological inhibitors or antagonists of the gene product.
The method of the invention can be used widely to address a question that applies to humans and innumerable other species that reside in our microbe-dominated world, namely how do bacteria contribute to and regulate the physiology and maturation of their hosts? In the case of humans, assembly and maintenance of a microflora undoubtedly involves intricate combinatorial regulatory mechanisms, developed over the course of a long selective process
that involved co-evolution of our predecessors with their microbial partners. The results presented below demonstrate the impact of an indigenous bacterial species on expression of genes that participate in vital physiologic functions, and emphasize the importance of viewing our biology as intertwined with the biology of our complex assemblies of resident bacteria.
The results also demonstrate the practicality of using defined in vivo models to deduce the responses of specified cellular populations within complex tissues to microbes, in a manner that preserves the influence of the surrounding cellular and environmental milieu.
These models and approaches will allow the pervasive contribution of microbes to human health to be evaluated and microbial products that are useful therapeutically to be identified. In addition, they should reveal how these normal host- microbial relationships affect various disease processes, and provide new perspectives and definitions about what constitutes a pathogenic relationship.
In addition however, the method has already revealed that a number of genes or gene products appear to have a significant effects in intestinal tissue, giving rise to the possibility that pharmaceuticals could be developed to target such genes or gene products in a manner which is beneficial to a patient. This can be done by screening for compounds which modulate the activity of the gene product .
A further aspect of the invention comprises a method for identifying genes that function as regulators of intestinal biology, said method comprising applying the method as described above and detecting expression genes which have not heretofore been associated with such function.
Thus a further aspect of the invention comprises a method of screening compounds having a pharmaceutical application in a gastrointestinal disease, which method comprises assaying the compounds for their ability to modulate the activity of the product of a gene identified using a method described above.
Yet a further aspect of the invention is a method of treating or preventing gastrointestinal disease which method comprises administering a therapeutically effective amount of a compound which modulates the activity of the product of a gene identified using a method according to claim 1.
In particular, on the basis of the results reported hereinafter, the invention further provides a method of screening for a compound potentially useful for treatment or prophylaxis of conditions characterized by a defect in intestinal barrier function which comprises assay of the compound for its ability to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2.
Suitable screening methods would be apparent to the skilled person. Once identified, the compounds are useful in the treatment or prophylaxis of conditions in which intestinal barrier function is comprised.
Thus a further aspect of the invention comprises the use of a compound able to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2 in preparation of a medicament for the treatment or prophylaxis of conditions characterized by a defect in intestinal barrier function.
Suitably, the compounds will be formulated as pharmaceutical compositions. Novel compositions of this type and their preparation form a further aspect of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the results of real-time quantitative RT-PCR studies of colonization-associated changes in gene expression in laser capture microdissected ileal cell populations, LCM of the ileum of a colonized mouse. Sections were stained with nuclear fast red. Bars=25μm.
Figure 2 shows the results of real-time quantitative RT-PCR analyses of mRNA levels in isolated from laser-captured cell populations. Values are expressed relative to levels in germ-free
mesenchyme using ΔΔCT analysis described below. Each gene product per sample was assayed in triplicate in 3-4 independent experiments. Representative results (mean± 1 S.D.) from pairs of germ-free and colonized mice are plotted.
Figure 3 shows the results of an experiment to illustrate the specificity of host responses to colonization with different members of the microflora. Germ-free mice were inoculated with one of the indicated organisms, or with a complete ileal/cecal flora from conventionally raised mice (Conv. microflora) ( 4) . Ileal RNAs, prepared from animals colonized at =107 CFU/ml ileal contents lOdays after inoculation, were pooled, and levels of each mRNA shown were analyzed by real time quantitative RT-PCR (qRT- PCR) . Mean values (±IS.D.) for triplicate determinations are plotted.
Figure 4 shows the nucleotide sequences of mouse angiogenin-4 and angiogenin-3 in alignment (SEQ ID NOS 29 and 30 respectively) .
Figure 5 illustrates the sequence alignment of the amino acid sequences of mouse angiogenin family members (SEQ ID NOS 31-34) .
Figure 6 shows the locations of primers specific for mouse angiogenin family members .
Figure 7 is a graph illustrating tissue distribution of angiogenin-4 mRNA, together with the results of an agarose gel analysis .
Figure 8 is a graph illustrating tissue distribution of angiogenin-1 mRNA.
Figure 9 is a graph illustrating tissue distribution of angiogenin-3 mRNA following quantitative real-time RT-PCR analysis.
Figure 10 shows the results of RT-PCR analysis showing the absence of angiogenin-related protein expression.
Figure 11 is a set of graphs showing the results of experiments on the microbial regulation of angiogenin-4 expression in the small intestine.
Figure 12 is a graph showing the regulation of angiogenin-4 expression during postnatal development.
Figure 13 is a block graph showing cellular localization of angiogenin-4 expression in small intestine: qRT-PCR analysis of cells isolated from the crypt base.
DETAILED DESCRIPTION OF THE INVENTION
In order to study at a molecular level, the changes in the intestine orchestrated by commensal bacteria, germ-free mice were colonised with commensal bacteria including Bacteroides thetaiotaomicron, a prominent component of the normal mouse and human intestinal microflora.
Global intestinal transcriptional responses to colonization were delineated using high-density oligonucleotide arrays and the cellular origins of specific responses established by laser capture microdissection and real-time quantitative RT-PCR. The results illustrated hereinafter, reveal that commensal bacteria modulate expression of a large number of genes, some to significant levels. The genes involved participate in diverse and fundamental physiological functions of the gut, including nutrient absorption, mucosal barrier fortification, and xenobiotic metabolism. The species-selectivity of some of the colonization- associated changes in gene expression emphasizes how human physiology can be impacted by changes in the composition of indigenous microflora.
Furthermore, it would appear that some commensals play a role in postnatal developmental transitions. Changes associated
with the suckling-weaning transition were elicited in adult mice by B. thetaiotaomicron, suggesting that indigenous bacteria play an instructive r,ole in postnatal gut development.
Coupling defined in vivo models with comprehensive genome- based analyses thus provides a powerful approach for identifying the critical contributions of resident microbes to host biology. Bacteroides thetaiotaomicron is a genetically-manipulatable anaerobe and was chosen for initial study to define the impact of resident bacteria on intestinal biology because it is a prominent member of both the adult mouse and human gut microflora. Moreover, B. thetaiotaomicron normally colonizes the distal small intestine (ileum) during the suckling-weaning transition, a time of rapid and pronounced functional maturation of the gut (W. E. C. Moore, L. V. Holdeman, Appl . Microbiol . 27, 961 (1974), T. Ushijima, M. Takahashi, K. Tatewaki, Y. Ozaki, Microbiol . Immunol . 27, 985 (1983) ) .
Colonization elicited a concerted response involving enhanced expression of four components of the host's lipid absorption machinery. mRNAs encoding pancreatic lipase related protein-2 (PLRP-2) and colipase increased an average of 4- and 9- fold, respectively (Tables 1 and 2) . PLRP-2 hydrolyzes tri- and diacylglycerols, phospholipids and galactolipids . Colipase augments PLRP-2 activity (M. E. Lowe, M. H. Kaplan, L. Jackson- Grusby, D. D'Agostino, M. J. Grusby, J. Biol . Chem. 273, 31215 (1998) ) . In addition, there was a 4-6-fold increase in L-FABP mRNA, which encodes an abundant cytosolic protein involved in fatty acid trafficking within enterocytes, and an induction of apolipoprotein AIV, a prominent component of triglyceride-rich lipoproteins (chylomicrons, VLDL) secreted from the basolateral surfaces of enterocytes (Table 1) .
Colonization led to an increase in ileal levels of NaVglucose cotransporter (SGLT-1) mRNA. There was also a concerted rise in expression of several components of the host' s lipid absorption/export machinery, including pancreatic lipase- related protein-2 (PLRP-2) , colipase, liver fatty acid binding
protein (L-FABP) , and apolipoprotein A-IV (See Table 1 hereinafter) . The prominent decrease in expression of fasting- induced adipose factor, a novel PPARα target known to be repressed with fat feeding (S. Kersten, et al . , J. Biol . Chem. 275, 28488 (2000).), provided further evidence for augmented lipid uptake in colonized mice.
The changes in expression of these 6 genes in particular indicate that B . thetaiotaomicron elicits an increased host capacity for nutrient absorption/processing and may provide a partial explanation as to why germ-free rodents require a higher caloric intake to maintain their weight than those with a normal microflora (B. S. ostmann, C. Larkin, A. Moriarty, E. Bruckner- Kardoss, Lab. Anim. Sci . 33, 46 (1983) .
Additionally, the applicants have found that colonisation produces changes in expression of four genes involved in dietary metal absorption. A high affinity epithelial copper transporter (CRT1) mRNA was increased, while metallothionein-I, metallothionein-II, and ferritin heavy chain mRNAs were decreased (Table 1) . These changes suggest that colonization engenders increased capacity to absorb heavy metals (e.g., via CRTl) and a concomitant decreased capacity to sequester them within cells (MT- I/II, ferritin) . This implies greater host demand for these compounds, either due to increased utilization by the host's own metabolic pathways or to competition with the microbe. The changes in SGLT-1, colipase, L-FABP, and MTl (plus 8 other mRNAs discussed below), were independently validated by qRT-PCR (C . Heid, J. Stevens, K.J. Livak, P.M. Williams, Genome Res . 6, 986 (1996) (see Table 2 below) .
Colipase plays a critical role in dietary lipid metabolism by stimulating the activity of both pancreatic triglyceride lipase and PLRP-2. Furthermore, proteolytic cleavage of procolipase yields a pentapeptide (enterostatin) that functions as a satiety signal for fat ingestion (S. Okada, D. A. York, G. A. Bray, Physiol . Behav. 49, 1185 (1991)). The significantly elevated expression found following colonisation with B. thetoaiotaomicron
illustrated hereinafter are indicative of a previously unappreciated mechanism by which the intestinal epithelium, together with a resident gut bacterium, contributes to dietary lipid metabolism. An intact mucosal barrier is critical for accomodating the vast population of resident intestinal microbes. Its disruption can provoke an immune response that is deleterious to the host and to the stability of luminal microflora, leading to pathologic states such as inflammatory bowel disease (P. G. Falk, et al., Microbiol . Mol . Biol . Rev. 62, 1157 (1998)).
It has been found that colonization with B. thetaiotaomicron produces no detectable inflammatory response, as judged by histologic surveys (L. Bry, P.G. Falk, T. Midtvedt, J. I. Gordon, Science 273, 1380 (1996) . Moreover, there is no discernible induction (or repression) of the many genes, represented on the microarrays, that are involved in responses. An influx of IgA-' producing B-cells does occur in the ileal mucosa lOdays after introduction of B. thetaiotaomicron; similar commensal-induced IgA responses have been shown to be T-cell independent and to enforce barrier integrity (A.J. Macpherson et al . , Science 288, 2222 (2000) .
Genes involved in barrier function account for 10% (7/71) of the changes in gene expression observed with B. thetaiotaomicron colonization. Microarray and qRT-PCR analyses revealed that the influx of IgA producing B-cells is accompanied by increased expression of the polymeric immunoglobulin receptor (plgR) that transports IgA across the epithelium (Tables 1,2). There is also augmented expression of the CRP-ductin gene, encoding both a component of the protective mucus layer overlying the epithelium (MUCLIN; R.C. DeLisle, et al . , Am. J. Physiol . 275, G219 (1998)) and a putative receptor for trefoil peptides that participate in fortification/healing of the intestinal mucosa (L.Thim, E. Mørtz, Regul . Pept . 90, 61 (2000) . Additionally, there is increased expression of decay accelerating factor (DAF) , an apical epithelial surface protein that inhibits complement-mediated
cytolysis (M.E. Medof, et al, J. Exp . Med. 165, 848 (1987) . Coincident enhancement of plgR, MUCLIN, and DAF expression should not only help prevent bacteria from crossing the epithelial barrier, but should also prevent mucosal damage that may ensue from microbial activation of complement components present in intestinal secretions.
It has been found that decay accelerating factor (DAF) expression increased 5-fold with colonization using B. thetaiotaomicron . DAF is known to be present on the apical surface of intestinal epithelial cells and to inhibit complement-mediated cytolysis (M.E. Medof, E.I. Walter, J.L. Rutgers, D.M. Knowles, V. Nussenzeig, J. Exp . Med. 165, 848 (1987)). The coincident enhancement of DAF, plgR, and MUCLIN expression should not only help prevent bacteria from crossing the epithelial barrier, but also prevent any mucosal damage that may ensue from microbial activation of complement components present in intestinal secretions .
The most pronounced response to B. thetaiotaomicron was an increase in small proline-rich protein-2 (sprr2a) mRNA (Table 1) . qRT-PCR analysis established that there is a 205+64-fold elevation in this mRNA with colonization (Table 2) . Sprr2a is a member of a family of proteins associated with terminal differentiation of squamous epithelial cells. Sprrs contribute to the barrier functions of squamous epithelia, both as a component of the cornified cell envelope, and as cross-bridging proteins linked to desmosomal desmoplakin , a prominent desmosomal constituent (P. M. Steinert, L. N. Marekov, Mol . Biol . Cell 10, 4247 (1999) . Colonization did not produce a notable change (i.e. two fold or more) , in the expression of genes encoding other proteins linked to desmosomes (desmoplakin, plakoglobin, plakophilin, plectin) , or tight junctions (ZO-1, occludin) .
Sprr2a expression in the intestine and its microbial regulation are novel findings. The critical contribution of sprr2a to the squamous epithelial barrier and the dramatic response of sprr2a expression to B . thetaiotaomicron together suggest that
this protein plays an important role in intestinal barrier function. It is therefore a particularly suitable target for further investigation in accordance with the invention, in particular by evaluating the biochemical pathway in which Sprr2a participates in the intestine.
A prominent marker of the weaning transition is the decline in lactase-phlorizin hydrolase (LPH) , an enterocytic brush-border enzyme that hydrolyzes the principal milk sugar, lactose. LPH mRNA levels rise throughout the small intestine of conventionally raised animals during the suckling period, and then fall in the ileum during weaning (S. D. Krasinski et al . , Am. J. Physiol . 267, G584 (1994) ) . The effects of commensal bacteria on expression of these genes in particular may be of interest in determining whether the bacteria have signficant impact. Using the method of the invention, it has been found that colonization results in increased expression of angiogenin-4 which resembles angiogenin-3, a secreted protein with demonstrated angiogenic activity (X. Fu, et al . , Mol . Cell Biol . 17, 1503 (1997), X. Fu, et al . , Growth Factors 17, 125 (1999)). The 11-fold increase in expression of the angiogenesis factor recognizable by amplification using primers of SEQ ID NO 12 and SEQ ID NO 25, which is angiogenin-4 (Table 1,2) upon B . thetaiotaomicron colonization represents a novel mode of regulation for an angiogenesis factor and so may be the subject of further investigation in accordance with the invention.
Laser capture microdissection (LCM) experiments described below have delineated the cellular origins of this response. This suggests that the presence of bacteria influences intestinal vascularization . The gut is the site of first contact of innumerable ingested toxins and xenobiotics . The relative contributions of luminal bacteria and the epithelium to detoxification and metabolism of
these compounds has been difficult to delineate in conventionally- raised mammals. It has been found that colonization of germ-free mice with B . thetaiotaomicron results in reduced expression of several genes involved in these processes (Table 1 below) . There is a decrease in the mRNA encoding glutathione S-transferase, which detoxifies a variety of electrophiles, and a corresponding decrease in multi-drug resistance protein-1 (Mdr-1) , which exports glutathione-conjugated compounds from the epithelium (R. W. Johnstone, A. A. Ruefli, M. J. Smyth, Trends Biochem . Sci . 25, 1 (2000)). Expression of CYP2D2 (debrisoquine hydroxylase) involved in oxidative drug metabolism in humans (M. Ingelman-Sundberg, et al., Trends Pharmacol . Sci . 20, 342 (1999), also declines with colonization. Reduced expression of these genes indicates that B . thetaiotaomicron may inself contribute to detoxification of compounds that are deleterious to the host.
A genetic polymorphism that produces a deficiency in this cytochrome P-450 is common in humans and associated with altered oxidative drug metabolism (M. Ingelman-Sundberg, M. Oscarson, R. A. McLellan, Trends Pharmacol . Sci . 20, 342 (1999)). The reduced expression of these three host genes suggests that commensal bacteria such as B . thetaiotaomicron contributes to the detoxification of compounds that could be deleterious to the host. This indicates that a component of the normal microflora can modulate host genes involved in drug metabolism, and underscore how variations in such metabolism between individuals may arise from differences in their resident gut flora. Consequently, evaluation of the effect on commensal bacteria on expression of these genes using the method of the invention may be helpful Pten is a member of a family of dual specificity protein phosphatases. PTEN haploinsufficiency in humans is associated with increased susceptibility to tumorigenesis (D. J. Marsh et al., Hum. Mol . Genet . 7, 507 (1998)). Furthermore,- Pten+/-**Pten+/+ chimeric mice develop colonic polyps and adenocarcinoma (A. DiCristofano, B. Pesce, C. Cordon-Cardo, P. P. Pandolfi, Na t .
Genet . 19, 348 (1998)). The human homolog of Gpl06, TB2/DP1, is a component of a locus which when mutated produces multiple intestinal adenomas (R. W. Burt, Adv. Exp. Med. Biol . 470, 99 (1999) ) . The finding that a component of the microflora affects expression of genes such as the angiogenesis factor whose gene is amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinafter) which is angiogenin-4, Pten and Gpl06 highlights the importance of considering mechanisms by which intestinal bacteria may contribute to the initiation or progression of tumorigenesis within, or even outside, the gut.
The motility of the intestine is regulated by its enteric nervous system (ENS) . The relative contributions of intrinsic and extrinsic factors to ENS activity are poorly understood, despite the fact that irritable bowel syndrome, which involves dysregulated motor activity, is a major health problem. The impact of commensal bacteria such as B. thetaiotaomicron on gut physiology extends to genes expressed in the enteric nervous system (ENS) and in the muscular layers. mRNAs encoding the L- glutamate transporter and L-glutamate decarboxylase, which converts glutamate to GABA, are both increased, suggesting a colonization-associated effect on the glutamatergic neurons of the ENS (M. T. Liu, J. D. Rothstein, M. D. Gershon, A. L. Kirchgessner, J. Neurosci . 17, 4764 (1997) ) . Enhanced expression of vesicle-associated protein-33, a synaptobrevin-binding protein involved in neurotransmitter release (P.A. Skehel et al., Proc.
Natl . Acad. Sci. U. S.A. 97, 1101 (2000) is also observed. There is a concomitant increase in two muscle-specific mRNAs: enteric γ- actin and cysteine-rich protein 2. Previous electrophysiological studies of germ-free and conventionally-raised animals have suggested that the microflora plays a role in gut motility (E. Husebye, P. M. Hellstrom, T. Midtvedt, Dig. Dis . Sci . 39, 946 (1994) ) . The method of the invention can provide molecular details about how resident gut microbes, such as B. thetaiotaomicron, may act to modulate motility.
23. thetaiotaomicron normally colonizes mouse and human intestine during weaning (W. E. C. Moore, L. V. Holdeman, Appl . Microbiol . 27, 961 (1974), T. Ushiji a, M. Takahashi, K. Tatewaki, Y. Ozaki, Microbiol . Immunol . 27, 985 (1983)). This period is characterized by a dramatic shift in the composition of the microflora and by a series of critical developmental changes in the intestinal epithelium. It is unclear how many of these changes are regulated by intrinsic cellular mechanisms, and how many are controlled by extrinsic signals emanating from the mesenchyme, or from luminal (dietary, microbial) factors.
Expression profiling revealed surprisingly that colonization of adult germ-free mice with B. thetaiotaomicron elicits other responses that mimic changes which normally occur in the maturing intestine of conventionally-reared animals. Expression of lactase, which hydrolyzes the principal milk sugar (lactose) , normally declines during the weaning period (S.D. Krasinski et al . , Am . J. Physiol . 267, G584 (1994) . Colonization of adult germ-free mice with B. thetaiotaomicron produces a decrease in ileal lactase mRNA (Table 1,2 below) . These findings indicate how members of the emerging postnatal normal flora may contribute to intestinal maturation.
Adenosine deaminase (ADA) and polyamines (spermine, spermidine) play important roles in postnatal intestinal maturation (G. D. Luk, L. J. Marton, S. B. Baylin, Science 210, 195 (1980), J. M. Chinsky, et al . , Differentiation 42, 172
(1990) ) . It has been found that B. thetaiotaomicron colonization produces an increase in mRNAs encoding ADA and ornithine decarboxylase (ODC) antizyme but not a 5-fold increase. The antizyme, whose expression is affected by polyamine levels, is a critical regulator of ODC turnover (J. Nilsson, S. Koskiniemi, K.
Persson, B. Grahn, I. Holm, Eur. J. Biochem . 250, 223 (1997)); an increase in antizyme mRNA levels therefore suggests that t colonization influences ileal polyamine synthesis. These data demonstrate that genes controlling synthesis of two classes of regulators of gut maturation, adenosine and polyamines, are
themselves modulated by a component of the microflora, leading to the idea that bacteria serve as upstream effectors of a cascade that affects gut maturation. Other colonization experiments, described below, indicate that other gut commensals have the capacity to engineer such changes.
Changes in gut maturation associated with the suckling- weaning transition are also thought to be regulated by increases in glucocorticoids (S. J. Henning, D. C. Rubin, R. J. Shulman, in Physiology of the Gastrointestinal Tract, L. R. Johnson, Ed. (Raven Press, New York, 1994), pp. 584-586). B. thetaiotaomicron colonization as described hereinafter was accompanied by reduced expression of two genes whose transcription is known to be suppressed by glucocorticoids: 15-hydroxyprostaglandin dehydrogenase (M. D. Mitchell, V. Goodwin, S. Mesnage, J. A. Keelan, Prostaglandins Leukot . Essent . Fatty Acids 62, 1 (2000)) and glucocorticoid-attenuated response gene-16 (J. B. Smith, H. R. Herschman, J. Biol . Chem 270, 16756 (1995)). Furthermore, there was reduced expression of another gene whose product interacts with nuclear hormone receptor family members, the immunophilin FKBP51 (S. C. Nair et al., Mol . Cell . Biol . 17, 594 (1997)). However, the reduction was not greater than 5-fold in any individual case. Thus, other commensal bacteria may be investigated using the method of the invention to see if these could produce a more significant effect. As mentioned above, the applicants have found that a particular member of the angiogenin family, whose gene is amplifiable using primers of SEQ ID NO 12 and 25 above and is expressed in mouse intestine, is novel. Thus this protein and the gene encoding it forms a further aspect of the invention. A further aspect of the invention provides a protein of SEQ ID NO 29 as shown in Figure 4 hereinafter, or an allelic variant thereof or a protein which has at least 85% amino acid sequence identity with SEQ ID NO 29.
In particular, the invention provides a protein of SEQ ID NO 29.
In yet a further aspect, the invention provides a nucleic acid which encodes a protein as described above.
These proteins are useful as a target for the screening process of the invention. The following Examples illustrate the invention. Example 1
Age-matched groups of 7-15 week-old germ-free NMRI/KI mice were maintained in plastic gnotobiotic isolators on a 12hour light cycle, and given free access to an autoclaved chow diet (B&K Universal) . Males were inoculated with wild-type B. thetaiotaomicron (strain VPI-5482) (L. Hooper et al (1999) supra) . Mice were sacrificed 10 days later, 2hours after lights were turned on. The distal 1 cm of the small intestine was used to define the number of colony forming units per ml of extruded luminal contents .
Ileal RNA was isolated from mice with >107 colony forming units (CFU) of bacteria per ml of luminal contents. [Earlier studies had shown that 10 days was sufficient to produce robust colonization of the ileum and that =107 CFU/ml were necessary for full induction of fucosylated glycan production in the ileal epithelium (L Hooper et al, (1999) supra. L. Bry, P. G. Falk, T. Midtvedt, J. I. Gordon, Science 213, 1380 (1996))].'
Total ileal RNA samples, prepared from the 3 cm of intestine adjacent the distal 1 cm of the small intestine of 4 mice from 3 independent colonizations, and from age- and gender-matched germ- free mice (n=8), using a RNA (Qiagen RNeasy kit), were each pooled, in equal amounts, for generation of biotinylated cRNA targets. Two targets were prepared, independently, from 30μg of each total cellular RNA pool, using the method outlined by C. K. Lee, et al . , Science 285, 1390 (1999) .
SYBR gre.en-based real-time quantitative RT-PCR studies ( N. Steuerwaldet al . , Mol . Hum. Reprod. 5, 1034 (1999)) were performed using the gene-specific primers listed in Table 3 below and DNAse- treated RNAs . Control experiments established that the signal for each
amplicon was derived from cDNA and not from primer di ers or genomic DNA. Signals were normalized to an internal reference mRNA (glyceraldehyde 3-phosphate dehydrogenase) . The normalized data were used to quantitate the levels of a given mRNA in germ-free and colonized ileums (ΔΔCT analysis; Bulletin #2, ABI Prism 7700 Sequence Detection System) .
Table 3 o cn H U α. gene name forward primer SEQ reverse primer SEQ
ID ED
NO NO
Na+/glucose cotransporter 5'- CAGAGACCCCATTACTGGAGAC 1 5'- TCGTTGCACAATGACCTGATC 14
(SGLTl) A colipase 5'- TGACACCATCCTGGGCATT 2 5'- ACACCGGTAGTAAATCCCATAA 15
AGG liver fatty acid binding protein (L- 5'- CTCCGGCAAGTACCAATTGC 5'- TGTCCTTCCCTTTCTGGATGAG 16
FABP) metallothionein I (MT-I) -, 5'- ATGTGCCCAGGGCTGTGT 4 5'- AACAGGGTGGAACTGTATAGGA 17
AGAC polymeric immunoglobulin receptor 5'- CTTCCCTCCTGTCCTCAGAGGT 5 5'- GGCGTAACTAGGCCAGGCTT 18
(pigR) decay accelerating factor (DAF) 5'- CAACCCAGGGTACAGGCTAGTC 6 5'- GGTGGCTCTGGACAATGTATTTC 19 small proline-rich protein 2a 5*- CCTTGTCCTCCCCAAGCG 7 5'- AGGGCATGTTGACTGCCAT 20
(sprr2a) multi-drug resistance protein 5'- GCCGCTTCTTCCAAAGTCTACA 8 5'- CGTGTCTCTACTCCCGGTTTCC 21
(mdrla) glutathione S-transferase (GST) 5'- CATCCAGCTCCTAGAAGCCATT 9 5'- GGGTTGCAGGAACTTCTTAATTG 22
TA lactase-phlorizin hydrolase 5*- TTGAATGGGCCACAGGCT 10 5'- AGCGGACTATGGAGGCGTAG 23
90 adenosine dearninase (ADA) 5'- GCGCAGTAAAGAATGGCATTC 11 5'- CTGTCTTGAGGATGTCCACAGC 24 angiogenin-4 5*- TCGATTCCAGGTCACCACTTG 12 5'- CACAGGCAATAACAATATATCT 25 o o GAAATCT glyceraldehyde 3 -phosphate 5'- TGGCAAAGTGGAGATTGTTGCC 13 5'- AAGATGGTGATGGGCTTCCCG 26 dehydrogenase
Each cRNA was hybridized to Affymetrix MullK and Mul9K chip sets representing ~25,000 unique mouse genes from Unigene Build 4 and the TIGR cluster databases, according to Affymetrix protocols. Data collected from each chip were scaled so that the overall fluorescence intensity across each chip was equivalent (target intenstity=150) . Pairwise comparisons of ■"germ-free' versus ^colonized' expression levels were performed.
A 2-fold or more difference was recorded if three criteria were met: the GeneChip software returned a difference call of "increased" or "decreased", the mRNA was called Λpresent' by GeneChip software in either germ-free or colonized cRNA, and the difference was observed in duplicate microarray hybridizations . mRNAs represented by 118 probe sets changed by at least 2- fold with colonization, as defined by duplicate microarray hybridizations .
It was found that transcripts represented by 95 probe-sets were increased, while those represented by 23 probe-sets were decreased. The genes represented by 84 of these probe sets (71 unique genes) were assigned to functional groups and these are set out in Table 1 hereinafter. In this table, results are presented as the fold-difference in mRNA levels between colonized and germ-free ileum and represent average values from duplicate microarray hybridizations. The average fold-changes for genes represented by 2 or more independent probe sets are listed separately.
These probe sets do not distinguish between family members
Table 1
Colonization-associated changes in distal small intestinal gene expression
Importantly, a large of number of the genes identified using these criteria are involved in modulating fundamental intestinal functions: 20 of the 71 genes (28%) were grouped under nutrient uptake and metabolism. There was also a concerted rise in expression of several components of the host's lipid absorption/export machinery, including pancreatic lipase-related protein-2 (PLRP-2) , colipase, liver fatty acid binding protein (L-FABP) , and apolipoprotein A-IV (Table 1) . The prominent decrease in expression of fasting-induced adipose factor, a novel PPARg target known to be repressed with fat feeding (S. Kersten, et al . , J. Biol . Chem. 275, 28488 (2000), provided further evidence for augmented lipid uptake in colonized mice. The changes in expression of these 6 genes indicate that B. thetaiotaomicron elicits an increased host
capacity for nutrient absorption/processing and helps explain why germ-free rodents require a higher caloric intake to maintain their weight than those with a microflora.
Additionally, there were changes in expression of four genes involved in dietary metal absorption. A high affinity epithelial copper transporter (CRT1) mRNA was increased, while metallothionein-I, metallothionein-II, and ferritin heavy chain mRNAs were decreased (Table 1) . These changes suggest that colonization engenders increased capacity to absorb heavy metals (e.g., via CRT1) and a concomitant decreased capacity to sequester them within cells (MT-I/II, ferritin) . This implies greater host demand for these compounds, either due to increased utilization by the host' s own metabolic pathways or to competition with the microbe. The changes in SGLT-1, colipase, L-FABP, and MTl (plus 8 other mRNAs discussed below) , were independently validated by qRT-PCR (CA. Heid, J. Stevens, K.J. Livak, P.M. Williams, Genome Res . 6, 986 (1996). (Table 2) .
Of these, genes which were found to have a difference in expression levels of 5-fold or more as a result of B. thetaiotaomicron colonisiation were colipase, liver fatty acid binding protein, fasting-induced adipose factor, metallothionein I and metallothionein II, malate oxidoreductase, Sprr2a, angiogenin-3, angiogenin-related protein, angiogenin family, gelsolin, gpl06 (TB2/DP1) and rac 2. Of these, colipase, fasting-induced adipose factor, angiogenin 3 and Sprr2a genes showed a difference in expression levels of 9-fold or more.
A notable feature of the host response to B. thetaiotaomicron was the absence of detectable or changed expression of the many genes involved in immuno-inflammatory processes that are represented on the microarrays . These include genes involved in the NF-KB-regulated processes that are critical regulators of host responses to invasive pathogens (D. Elewaut et al . , J. Immunol . 163, 1457 (1999)). The absence of these responses can be contrasted to results obtained in a recent cDNA microarray analysis of the response of a human
intestinal epithelial cell line to Salmonella , an invasive gut pathogen (L. Eckmann, J. R. Smith, M. P. Housley, M. B. Dwinell, M. F. Kagnoff, J. Biol . Chem. 275, 14084 (2000)). The lack of evidence for an evoked in vivo iιm_uno-inflammatory response is consistent with the host' s need to accommodate resident gut microbes, such as B . thetaiotaomicron, for its entire lifespan.
Colonization increases expression of two genes implicated in development of gut neoplasia, Pten and Gpl06 (Table 1) . Example 2
In a further analysis two techniques were combined. First, laser-capture microdissection (LCM) was used to recover three cell populations from frozen sections of ileum harvested immediately after sacrifice of germ-free and colonized mice. The three populations are (i) epithelium present in crypts (the proliferative compartment of the intestine containing undifferentiated cells as well as differentiated members of the Paneth cell lineage) ; (ii) epithelium overlying villi (containing post-mitotic, differentiated members of the intestine's other three lineages); and (iii) mesenchyme underlying crypt-villus units (Fig. 1) .
LCM was performed on groups of mice independent of those used to generate RNA for the microarray analysis. 7μm-thick sections were cut from frozen ileums and LCM conducted using the PixCell II system from Arcturus (7.5μm diameter laser spot) . RNA was prepared from dissected cell populations using the RNA Micro-Isolation Kit (Strategene) and standard histochemical protocols. Laser capture microdissection (LCM) was carried out using conventional methods as described by MR Emmert-Buck et al., Science., 274, 998-1001, 1996 and R.F. Bonner et al., Science 278:1203-4, 1997. The results are shown in Figure 1.
Second, real-time RT-PCR was used to quantitate levels of specific mRNAs in the laser captured cell populations. The LCM/qRT-PCR analysis was performed using germ-free and colonized mice from 3 experiments that were independent of those used for microarray profiling.
Each sample was analyzed in triplicate in 4-independent
experiments. Mean values for the independent determinations +1 S.D. are shown in Table 2
Table 2 Real-time quantitative RT-PCR studies of colonization- associated changes in gene expression
Gene Fold Δ
(relative to germ-free)
Na+/glucose cotransporter (SGLTl) 2.6 + 0.9 colipase 6.6 + 1.9 liver fatty acid binding protein (L-FABP) 4.4 + 1.4 metallothionein I (MT-I) -5.4 + 0.7 polymeric immunoglobulin receptor (plgR) 2.6 + 0.7 decay accelerating factor (DAF) 5.7 + 1.5 small proline-rich protein 2a (sprr2a) 205 + 64 multi-drug resistance protein (mdrla) -3.8 + 1.0 glutathione S-transferase (GST) -2.1 + 0.1 lactase-phlorizin hydrolase -4.1 + 0.6 adenosine deaminase (ADA) 2.6 + 0.6 angiogenin-4 9.1 + 1.8
Colipase is produced by the exocrine (acinar) cells of the pancreas. Expression in the intestine had not been reported previously. Therefore, LCM and real-time RT-PCR analysis were employed to delineate the cellular origins of its response to B. thetaiotaomicron .
The results show that sprr2a mRNA is confined to the epithelium where its concentration is 7-fold higher on the villus compared to the crypt (Fig. IB) . B. thetaiotaomicron elicits a 280-fold increase in the villus epithelium. This value is in good agreement with the increase documented in total ileal RNA (Table 2) . The cellular origin of the sprr2a response supports the hypothesis that it participates in fortifying the intestinal epithelial barrier in reβponse to bacterial colonization.
Colipase is produced by the exocrine acinar cells of the pancreas. LCM/qRT-PCR revealed that colipase mRNA is also present in the ileal crypt epithelium, where it increases 10- fold upon B. thetaiotaomicron colonization (Fig. IB) . This accounts for the increase detected by microarray and qRT-PCR analyses of total ileal RNA (Tables 1,2). Colipase plays a critical role in dietary lipid metabolism by stimulating the activity of both pancreatic triglyceride lipase and PLRP-2 (M.E. Lowe, et al . , J. Biol . Chem. 273, 31215 (1998). Furthermore, proteolytic cleavage of procolipase yields a pentapeptide (enterostatin) that functions as a satiety signal for fat ingestion (S. Okada, et al . , Physiol . Behav. 49, 1185 (1991). Analyses of colipase gene regulation reveal a previously unappreciated contribution of the intestinal epithelium (together with a resident gut commensal) to dietary lipid metabolism.
Angiogenin-3 was originally identified in NIH 3T3 fibroblasts (X. Fu et al., Mol . Cell Biol . 17, 1503 (1997), but little is known about its cellular origins or regulation. LCM and qRT-PCR revealed that the crypt epithelium is the predominant location of a gene amplifiable using primers such as SEQ ID NO 12 and 25 (see Table 3 hereinbefore) which are specific for angiogenin-3 mRNA, but also for the new protein which is angiogenin-4 mRNA and that colonization results in a 7-fold increase in its levels within this compartment. This increase accounts for the change in expression defined by microarray and qRT-PCR analyses of total ileal RNA (Tables 1,2). The epithelial location of a secreted/RNAse/angiogenesis factor puts it in a strategic position to function as an effector of a number of host responses to microbial colonization (e.g., enhanced absorption/distribution of nutrients/augmented barrier function.
The LCM/qRT-PCR studies of sprr2a, colipase and angiogenin-4 establish the feasibility of assigning an in vivo host response to a particular cell population in a complex tissue, and of describing the cellular response in quantitative terms . In recovering a responding cell population and expressing its reaction to a microorganism in quantitative terms, the
applicants results demonstrate how it is possible to move beyond in vi tro models and use in vivo systems to study the impact of a microbe on host cell gene expression.
Colonization of germ-free mice with B. thetaiotaomicron produces a decrease in ileal LPH irtKNA levels (Table 1,2) (although not by as much as five times) . Analysis of RNA isolated from laser-captured epithelial and mesenchymal cell populations established that the colonization-induced reduction in LPH mRNA levels occurs primarily within the villus epithelium (Fig. 2) .
Comparison of transcript levels between germ-free and B . thetaiotaomicron-a.ssocia.ted mice revealed a colonization- associated increase in expression of angiogenin-4.
The 11-fold induction of its mRNA seen in Example 1 was independently validated by real-time RT-PCR of total ileal RNAs (Table 2) . Angiogenin-3 was originally identified in NIH 3T3 fibroblasts (X. Fu, M. P. Kamps, Mol . Cell Biol . 17, 1503 (1997) ) . However, LCM and real-time RT-PCR analysis revealed that in colonized ileum, the levels of mRNA which are amplifiable using primers designed for angiogenin-3 are highest in crypt epithelium (values in the ileal villus epithelium and mesenchyme are 14- and 15-fold lower, respectively; Fig. 2) . As outlined in Example 4 below however, this mRNA is in fact, angiogenin-4 mRNA. The 7-fold increase in these angiogenin-4 mRNA levels observed in the crypt epithelium after colonization account for the change defined by microarray and real-time RT-PCR analyses of total ileal RNA.
Bacterial modulation of epithelially-expressed angiogenin-4 represents a novel mode of regulation for an angiogenesis factor. Example 3
LCM/qRT-PCR established that colonization reduces lactase mRNA levels within the villus epithelium (Fig. IB) . The concept that microbes may help legislate changes in expression of developmentally-regulated genes, such as lactase, raises the question of whether some or many components of the microflora can elicit these changes .
In order to examine this, age-matched groups (n = 4-8 mice/group) of 7-15 week-old germ-free NMRI/KI mice were maintained in plastic gnotobiotic isolators on a 12hour light cycle, and given free access to an autoclaved chow diet (B&K Universal) . Males were inoculated with one of the following groups
(i) Nothing - Germ-free control,
(ii) B. thetaiotaomicron strain VPI-5482 (L.V. Hooper, et al . , Proc. Na tl . Acad. Sci . U. S. A. 96, 9833 (1999)), (iii) E. coli K12 which was originally recovered from a normal human fecal flora, (iv) Bifidobacterium infantis (ATCC15697) , a prominent component of the pre-weaning human and mouse ileal flora and a commonly used probiotic.
(v) a 'complete' ileal/cecal microflora harvested from conventionally-raised mice (L. Bry, et al . , Science 273, 1380 (1996)
A further control group comprised mice conventionally raised since birth.
Mice were sacrificed lOdays later, 2hours after lights were turned on. The distal 1 cm of the small intestine was used to define CFU/ml ileal contents. The 3 cm of intestine just proximal to this segment was used to isolate total ileal RNA (Qiagen RNeasy kit) . qRT-PCR was used to compare ileal lactase mRNA levels in each group (all animals had =107CFU/ml ileal contents) . The results are shown in Figure 3.
Colonization with any of the three gram-negative anerobes elicited an equivalent decline in lactase expression relative to germ-free controls (Fig. 3) . This decline was also observed after inoculation of a complete ileal/cecal flora. qRT-PCR of the same RNAs revealed that ileal expression of colipase and angiogenin-4 was induced after colonization of all three organisms, and by the ileal/cecal flora (Fig. 3) .
The levels of colipase and angiogenin-4 mRNAs achieved in the ileums of these ex-germ-free mice were comparable to those of age-matched mice that have been conventionally-raised since birth (Fig. 3) .
In contrast to these findings, the response of sprr2a to
colonization was dependent upon the colonizing species. While _-. thetaiotaomicron produced a pronounced rise in sprr2a mRNA that recapitulates the response to a lOday colonization with the ileal/cecal flora, colonization with B. infantis and E. coli produce only negligible increases in mRNA levels (Fig. 3) . Mdrla and glutathione-S-transferase, which act in concert to metabolize xenobiotics and electrophiles, also exhibited species-specific (and concerted) responses. Unlike B. thetaiotaomicron, which suppresses expression, E. coli and B. infantis both elicit increases in these mRNAs. In contrast, the multi-component ileal/cecal flora did not produce a significant (i.e. ,=2-fold) change in levels of either mRNA when compared to germ-free controls.
The Mdrla/GST responses provide direct evidence that components of the normal microflora can modulate host genes involved in drug metabolism, and suggest that variations in drug metabolism between individuals may arise, in part, from differences in their resident gut flora. Example 4 Following the observation that a lOd colonization was associated with a 11-fold increase in ileal expression of a mRNA detected by an Affymetrix-designed probe-set designed from the published sequence of angiogenin-3, we designed primers specific for the 3' and 5' ends of the mouse angiogenin-3. There were:
ORF [forward primer:
5'-CCTTGGATCCATGGTGATGAGCCCAGGT TCTTTG (SEQ ID NO 27)
which incorporates a BamHI site at the 5' end; reverse primer: 5'-CCTTTCTAGACTACGGACTGATAAAAGACTCATCGAAG (SEQ ID NO 28)
which incorporates an Xbal site at the 5' end. These primers were used together with RT-PCR to amplify a 438 bp sequence from RNA prepared from the ileums of ex-germ- free NMRI mice. These mice had been colonized, for lOd with a complete ileal/cecal flora harvested from conventionally-raised
animals belonging to the same inbred strain. We subcloned the PCR product into BamHI/Xbal digested pGEX-KG and sequenced it using vector-specific primers.
Surprisingly, the nucleotide sequence of the ORF was only 90% identical to that of mouse angiogenin-3. Since the primer sequences used in the PCR reaction (specific for angiogenin-3) were incorporated into the product, we used 5'- and 3' -RACE to (a) obtain accurate sequence at the 5' and 3' ends of the ORF of this new angiogenin, and (b) characterize the 5'- and 3'- untranslated regions of its mRNA. The results revealed only 88.3% nucleotide sequence identity with angiogenin-3 mRNA.
The nucleotide sequence which encodes the angiogenin-4 protein, aligned with the angiogenin-3 sequence is shown hereinafter in Figure 4 as SEQ ID NO 29 and 30 respectively. - Angiogenin-4 has 74 to 81% amino acid sequence identity to the other 3 members of the mouse angiogenin family (Figure 5) . It was found that the 5' and 3' -untranslated regions of angiogenin-4 are closely related to the corresponding regions of angiogenin-3 mRNA (Figure 4) . Subsequently a comparative analysis of the tissue distribution of the various mouse angiogenin mRNAs, was conducted. cDNA was synthesized from RNAs isolated from tissues harvested from conventionally raised adult (12-14 week old) male and female NMRI mice (25 tissues/mouse) . To quantitate relative levels of expression of each gene, we designed primer sets specific for each of the four mouse angiogenin family members (Figure 6; Table 4) and used them for SYBR-Green-based real-time quantitative RT-PCR (qRT-PCR) analyses . Remarkably, angiogenin-4 mRNA was restricted the intestine where it is expressed from the duodenum to the rectum (Figure 7) . In contrast, angiogenin-1 expression is highest in liver, lung, and pancreas (Figure 8) , while angiogenin-3 is expressed primarily in liver, lung, pancreas, and prostate (Figure 9) . Angiogenin-related protein mRNA was undetectable in all tissues surveyed even after 40 cycles of PCR (Figure 10) .
Thus, the highly restricted, intestine-specific pattern of angiogenin-4 expression makes it unique among mouse angiogenin
family members .
These findings indicated that there was microbial- regulation of angiogenin-4 rather than angiogenin-3 expression in the intestine. To test this hypothesis directly, angiogenin-4-specific primers and qRT-PCR were used to compare angiogenin-4 mRNA levels along the length of the small intestine of germ-free NMRI mice and germ-free mice colonized for 10 d with an ileal/cecal flora harvested from conventionally raised NMRI animals. Pair-wise comparisons revealed that expression of angiogenin-4 is highest in the jejunum of colonized mice, and that conventionalization induces up to a 17-fold increase in angiogenin-4 expression in this region (Figure 11) . Mono-association of germ-free NMRI mice with B. thetaiotaomicron for lOd resulted in a comparable induction of angiogenin-4 expression (data not shown) .
Table 4
Gene Primer SEQ ID Sequence NO angiogenin-4 forward 35 5' CTCTGGCTCAGAATGTAAGGTACGA reverse 36 5* GAAATCTTTAAAGGCTCGGTACCC
angiogenin-3 forward 37 5' CTGGCTCAGGATAACTACAGGTACAT reverse 38 5' GCCTGGGAGACCCTCCTTT angiogenin- 1 forward 39 5' AGCGAATGGAAGCCCTTACA reverse 40 5' CTCATCGAAGTGGACCGGCA
angiogenin- forward 41 5' GGTGAAAAGAAAGCTAACCTCTTTC related protein reverse 42 5' AGACTTGCTTATTCTTAAATTTCG
Regulation of angiogenin-4 expression during postnatal development is consistent with its microbial regulation
The developmental patterns of angiogenin-4 expression in postnatal day 5 (P5) - P30 germ-free and conventionally raised NMRI mice (n = 3 mice per time point per group) was then assessed (Figure 9) . Relative levels of the angiogenin-4 transcript remained relatively low until P20 in both groups of mice. Expression rose slightly (2-3 fold) in germ-free animals after this time point. In contrast, angiogenin-4 expression increased more than 20-fold between P15 and P30 in
conventionally-raised animals. These results indicate that angiogenin-4 is induced during the suckling/weaning transition - coincident with a major shift in the gut microbiota. The lack of angiogenin-4 induction in postnatal germ-free mice is also consistent with the conclusion that components of the microbiota play an important role in regulating angiogenin-4 expression.
Cellular localization of angiogenin-4
The previous laser capture microdissection (LCM) /qRT-PCR study of the cellular origins of angiogenin protein expression (Example 2) used primers that recognize both angiogenin-3 and angiogenin-4, and RNAs that had been isolated from captured crypt epithelium, villus epithelium, or mesenchymal populations from the villus core. The qRT-PCR analysis indicated that the icrobially-regulated angiogenin' was produced in epithelial cells located at the base of crypts of Lieberkuhn (Hooper et al., 2001) .
To test the hypothesis that angiogenin-4 expression occurs in Paneth cells, we used LCM to isolate cells located at the base of jejunal crypts from (a) germ-free adult (12 week old) transgenic mice with an attenuated diphtheria toxin-A fragment ( toxl 76) -mediated Paneth cell lineage ablation (CR2-tc__176 mice) (Garabedian et al., 1997), and (b) their age and gender- matched germ-free normal littermates . qRT-PCR using angiogenin- 4-specific primers revealed that angiogenin-4 mRNA levels are
10-fold higher in RNA purified from crypt base epithelial cells of normal mice compared to CR2-toxl76 littermates (Figure 10) .
A follow-up study was conducted using conventionally raised NMRI mice. Three cellular pools were harvested by LCM: Paneth cells alone, epithelial cells from the upper crypt and villus (a Paneth cell-minus fraction) , and mesenchyme retrieved from the villus core and the peri-cryptal region. The distribution of angiogenin-4 mRNA closely paralleled the distribution of phospholipase A2 - the product of the Mom-1 locus and a well-known Paneth cell-specific gene product (data not shown) .
Claims
1. A method of investigating chemical changes resulting from commensal microflora colonisation of mammalian intestine which comprises: a) measuring gene expression in commensal bacterium-colonized and germ-free intestine of at least one gene; and b) identifying a gene from a) that has at least a 2-fold difference in expression level between commensal bacterium-colonized and germ-free intestine.
2. A method according to claim 1 wherein in step (a) multiple gene expression is measured by DNA microarray analysis and/or quantitative RTPCR.
3. A method according to claim 1 which further comprises the step of c) investigating a gene identified in b) with regard to its function, in a system selected from the group consisting or in vitro cell culture, lower eukaryotic model organisms or an animal model.
4. A method according to claim 3 wherein the function is studied using a method selected from the group consisting of i) transgenic knockout; ii) dominant-negative experiments; iii) transgene overexpression; iv) antibody binding assay; v) by pharmacological intervention using defined chemical agents .
5. A method according to claim 1 wherein the commensal bacteria is B. thetaiotaomicron .
6. A method according to claim 1 wherein expression of at least 10 genes is measured and said genes are selected from genes associated with the nutrient uptake and metabolism, hormone/maturational responses, mucosal barrier function, detoxification/drug resistance, enteric nervous system/muscular layer development or activity, angiogenesis, cytoskeleton/extracellular matrix function or development, signal transduction or other cellular r functions are measured in step (a) .
7. A method according to claim 6 wherein expression of at least 10 genes selected from the group consisting of genes encoding Na+/glucose cotransporter (SGLTl) , lactase phlorizin-hydrolase, pancreatic lipase-related protein 2, colipase, liver fatty acid binding protein, fasting induced adipose factor (FIAF) , apolipoprotein A-IV, phospholipase B, CYP27 high-affinity copper transporter, metallothionein I, metallothionein II, ferritin heavy chain, isocitrate dehydrogenase subunit, succinyl CoA transferase, transketolase, malate oxidoreductase, aspartate aminotransferase, adenosine deaminase, omithine decarboxylase antizyme, 15-hydroxyprostaglandin dehydrogenase, GARG-16, FKBP51, androgen-regulated vas deferens protein, short chain dehydrogenase, heat-stable antigen, decay-accelerating factor, polymeric Ig receptor, small proline-rich protein 2a, serum amyloid A protein, CRP-ductin (MUCLIN) , zeta proteasome chain, anti-DNA IgG light chain, glutathione S-transferase, P-glycoprotein (mdrla), CYP2D2 , L-glutamate transporter, L-glutamate decarboxylase, vesicle-associated protein-33, cysteine-rich protein 2, smooth muscle (enteric) gamma actin, SM-20, angiogenin-4, gelsolin, destrin, alpha cardiac actin, endoB cyto eratin, fibronectin, proteinase inhibitor 6, alpha 1 type 1 collagen, Pten, gpl06 (TB2/DP1), rac2 ,
Semcap2, serum and glucocorticoid-regulated kinase, STE20- like protein kinase and B-cell myeloid kinase, glutathione reductase, calmodulin, elF3 subunit, hsc70, oligosaccharyl transferase subunit, fibrillarin, H+-transporting ATPase and Msec23.
8. A method according to claim 6 wherein said 10 genes include genes encoding colipase, decay-accelerating factor (DAF) , the polymeric IgA receptor, small proline-rich protein 2a (Sprr2a) , angiogenin-3, angiogenin-4, Pten, CYP2D2 , Sprr2a, rac2 and Mdr-1.
9. A method according to claim 7 wherein expression of substantially all of said genes is measured.
10. A method according to claim 1 wherein in step (b) a gene for which at least a 7 -fold difference in expression is identified.
11. A method according to claim 3 which comprises evaluation of the biochemical pathway in which angiogenin-4 or colipase participates in the intestine.
12. A method of changing the expression levels of a particular gene within the digestive tract of a mammal for therapeutic or prophylactic purposes, said method comprises altering the density in the gastrointestinal tract of a commensal bacteria identified using a method according to claim 1 as being able to produce the desired change in said expression level .
13. A method according to claim 12 which comprises modulating epithelially-expressed angiogenesis factor using an effective commensal bacteria identified using a method of claim 1.
14. A method according to claim 12 which comprises modifying metabolism using an effective commensal bacteria identified using a method according to claim 1.
15. A method according to claim 12 which comprises modifying epithelial barrier function using an effective commensal bacteria identified using a method according to claim 1.
16. A method of screening compounds having a pharmaceutical application in a gastrointestinal disease, which method comprises assaying the compounds for their ability to modulate the activity of the product of a gene identified using a method according to claim 1.
17. A method of treating or preventing gastrointestinal disease which method comprises administering therapeutically effective amount of a compound which modulates the activity of the product of a gene identified using a method according to claim 1.
18. A method of screening for a compound potentially useful for treatment or prophylaxis of conditions characterized by a defect in intestinal barrier function which comprises assay of the compound for its ability to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2.
19. The use of a compound able to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2 in preparation of a medicament for the treatment or prophylaxis of conditions characterized by a defect in intestinal barrier function.
20. A method of treating or preventing conditions characterized by a defect in intestinal barrier function which method comprises administration of a therapeutically effective amount of a compound which is able to modulate the activity or amount of small proline-rich protein 2a (sprr2a) or rac2.
21. A method for identifying genes that function as regulators of intestinal biology, said method comprising applying the method as claimed in claim 1 and detecting expression genes which have not heretofore been associated with such function.
22. An angiogenin protein encoded by a gene, at least part of which is amplifiable using primers of SEQ ID NO 12 and 25 above, which is expressed in mouse intestine.
23. A protein according to claim 22 wherein the protein is of SEQ ID NO 29 as shown in Figure 4 hereinafter, or an allelic variant thereof or a protein which has at least 85% amino acid sequence identity with SEQ ID NO 29.
24. A protein according to claim 23 which is of SEQ ID NO 29.
25. A nucleic acid which encodes a protein according to claim 22.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25290100P | 2000-11-27 | 2000-11-27 | |
| US252901P | 2000-11-27 | ||
| PCT/US2001/044332 WO2002042328A2 (en) | 2000-11-27 | 2001-11-27 | Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1414853A2 true EP1414853A2 (en) | 2004-05-06 |
Family
ID=22958021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01995938A Withdrawn EP1414853A2 (en) | 2000-11-27 | 2001-11-27 | Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1414853A2 (en) |
| JP (1) | JP2004536557A (en) |
| AU (1) | AU2002226984A1 (en) |
| WO (1) | WO2002042328A2 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1529054A4 (en) * | 2001-11-27 | 2005-12-28 | Univ Washington | THERAPEUTIC PROTEIN AND TREATMENTS |
| US20050239706A1 (en) * | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
| DE102005026710A1 (en) * | 2005-06-09 | 2006-12-14 | Basf Ag | Method for testing substances or substance mixtures, their use and corresponding analysis kits |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| AR103260A1 (en) | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | IMMUNE MODULATION |
| EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41060B1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41010B1 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT201900588T1 (en) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN108513545B (en) | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | Compositions comprising bacterial strains |
| ME03487B (en) | 2016-03-04 | 2020-01-20 | 4D Pharma Plc | BACTERIAL BLAUTIA STRAIN COMPOSITIONS FOR THE TREATMENT OF VISCERAL HIGH SENSITIVITY |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI802545B (en) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | Compositions comprising bacterial strains |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| DK3630136T3 (en) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | COMPOSITIONS INCLUDING BACTERIA STRAINS |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT202000555T1 (en) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Compositions comprising a bacterial strain of the genus megasphaera and uses thereof |
| SMT202000695T1 (en) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Compositions comprising bacterial strains |
| CN110777215A (en) * | 2019-11-07 | 2020-02-11 | 北京市心肺血管疾病研究所 | A method for detecting whether food contains C2Z7 transgenic maize by using metagenomic technology |
| CN116143899B (en) * | 2022-11-07 | 2024-02-20 | 四川农业大学 | A recombinant antibacterial peptide pANG4 and its preparation method and application |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
| EP1196633A2 (en) * | 1999-04-23 | 2002-04-17 | Clontech Laboratories Inc. | Methods and compositions for performing array based hybridization assays |
-
2001
- 2001-11-27 WO PCT/US2001/044332 patent/WO2002042328A2/en not_active Ceased
- 2001-11-27 EP EP01995938A patent/EP1414853A2/en not_active Withdrawn
- 2001-11-27 JP JP2002544461A patent/JP2004536557A/en active Pending
- 2001-11-27 AU AU2002226984A patent/AU2002226984A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0242328A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004536557A (en) | 2004-12-09 |
| WO2002042328A2 (en) | 2002-05-30 |
| WO2002042328A3 (en) | 2004-02-19 |
| AU2002226984A1 (en) | 2002-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002042328A2 (en) | Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon | |
| Sreekumar et al. | Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis | |
| US20050239706A1 (en) | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject | |
| Mueller et al. | Profiling of microdissected gastric epithelial cells reveals a cell type—specific response to Helicobacter pylori infection | |
| Wang et al. | An extract of Artemisia dracunculus L. enhances insulin receptor signaling and modulates gene expression in skeletal muscle in KK-Ay mice | |
| US20040091893A1 (en) | Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon | |
| CN102150046A (en) | Use of Cathepsin C | |
| US20060003959A1 (en) | Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same | |
| Shoji et al. | Five novel SLC7A7 variants and y+ L gene‐expression pattern in cultured lymphoblasts from Japanese patients with lysinuric protein intolerance | |
| JP2006508642A (en) | Methods for reducing fat accumulation and methods for treating related diseases | |
| EP2758778A1 (en) | Screening method | |
| Van Der Meer-Van Kraaij et al. | Mucosal pentraxin (Mptx), a novel rat gene 10‐fold down‐regulated in colon by dietary heme | |
| US7241571B2 (en) | Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis | |
| Dutta et al. | Hepatic gene expression profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor and Apobec1 genes | |
| US20050158733A1 (en) | EGR genes as targets for the diagnosis and treatment of schizophrenia | |
| US20100285483A1 (en) | Molecular diagnostic method and treatment in dementia with Lewy bodies | |
| US20030036079A1 (en) | Gene expression alterations underlying the retardation of aging by caloric restriction in mammals | |
| Jerez‐Timaure et al. | Characterization of QTL with major effects on fatness and growth on mouse chromosome 2 | |
| US20040131658A1 (en) | Identification of diet-regulated disease-associated genes | |
| AU2004219599A1 (en) | Methods of evaluating caloric restriction and identifying caloric restriction mimetics | |
| CA2405548A1 (en) | Steatosis-modulating factors and uses thereof | |
| US7442509B2 (en) | Detecting mutations in the feline cardiac myosin binding protein C gene associated with hypertrophic cardiomyopathy in cats | |
| CN110079619A (en) | Detect the specific primer of four kinds of glycopeptide class Drug-resistant genes and probe combinations and application in gram-positive bacterium | |
| US9157119B2 (en) | Methods for diagnosing skin diseases | |
| CN121272040A (en) | Application of SETD2 and NSD2 in diagnosis and treatment of intestinal stem cell aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| 17P | Request for examination filed |
Effective date: 20040819 |
|
| 17Q | First examination report despatched |
Effective date: 20050103 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: WASHINGTON UNIVERSITY |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20080603 |